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Abstract 
 
Single nucleotide variants (SNVs) that occur in transcription factor binding 
sites (TFBSs) can disrupt the binding of transcription factors and alter gene 
expression which can cause inherited diseases and act as driver SNVs in 
cancer. The identification of SNVs in TFBSs has historically been 
challenging given the limited number of experimentally characterised TFBSs. 
The recent ENCODE project has resulted in the availability of ChIP-Seq data 
that provides genome wide sets of regions bound by transcription factors. 
These data have the potential to improve the identification of SNVs in 
TFBSs. However, as the ChIP-Seq data identify a broader range of DNA in 
which a transcription factor binds, computational prediction is required to 
identify the precise TFBS. Prediction of TFBSs involves scanning a DNA 
sequence with a Position Weight Matrix (PWM) using a pattern matching 
tool.  
This thesis focusses on the prediction of TFBSs by: (a) evaluating a set of 
locally-installable pattern-matching tools and identifying the best performing 
tool (FIMO), (b) using the ENCODE ChIP-Seq data to evaluate a set of de 
novo motif discovery tools that are used to derive PWMs which can handle 
large volumes of data, (c) identifying the best performing tool (rGADEM), (d) 
using rGADEM to generate a set of PWMs from the ENCODE ChIP-Seq 
data and (e) by finally checking that the selection of the best pattern 
matching tool is not unduly influenced by the choice of PWMs. 
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These analyses were exploited to obtain a set of predicted TFBSs from the 
ENCODE ChIP-Seq data. 
 The predicted TFBSs were utilised to analyse somatic cancer driver, and 
passenger SNVs that occur in TFBSs. Clear signals in conservation and 
therefore Shannon entropy values were identified, and subsequently 
exploited to identify a threshold that can be used to prioritize somatic cancer 
driver SNVs for experimental validation.     
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1 Introduction 
This thesis is concerned with identifying and understanding the effects of 
Single Nucleotide Variants (SNVs) that occur in transcription factor binding 
sites (TFBSs). This is an area where little research has been carried out. 
This is in contrast to the large volume of research that has been carried out 
on investigating and predicting the effects of non-synonymous SNVs on 
protein structure and function.   
1.1 Single Nucleotide Variants 
SNVs are the most common form of genetic variation. SNVs are point 
mutations that result in base substitutions (Altshuler et al., 2010; Cline and 
Karchin, 2011). SNVs arise as a result of errors in the DNA replication 
process where DNA polymerases insert incorrect nucleotides that go 
undetected by the genome maintenance systems, and therefore are not 
corrected. SNVs can also arise as a result of exposure to radiation or 
chemical agents. There are two types of SNVs: germline and somatic.  
Germline SNVs are SNVs that occur in the germ cells (cells that are destined 
to become the egg cell or a sperm cell) and are subsequently passed on to 
the offspring. Certain germline SNVs cause inherited diseases. An inherited 
disease is a disorder that results from a mutation in a single gene and has 
100% penetrance. Examples include cystic fibrosis and sickle cell anaemia.    
Somatic SNVs are SNVs that occur in somatic cells i.e. cells that are not 
gametes and are not passed on to offspring. Certain somatic SNVs act as 
drivers in cancer. DNA sequencing is used to detect germline SNVs causing 
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inherited diseases and somatic SNVs acting as drivers in cancer (Jamuar 
and Tan, 2015; Chong et al., 2015; Pabinger et al., 2014; Watson et al., 
2013; Klug et al., 2012).  
   
1.2 Whole Genome Sequencing 
The cost of DNA sequencing has fallen sharply in recent years beating 
Moore’s law (Sboner et al., 2011). Moore’s law states that computer 
processing  power will double every two years (Moore, 1998). Today it is 
possible to sequence an entire human genome for less than $1000 (Hayden, 
2014). This makes it affordable for whole genome sequencing to become 
commonplace (see http://www.genomicsengland.co.uk/the-100000-
genomes-project/). With the cost of genome sequencing continuing to fall, it 
will soon be cheaper to conduct whole genome sequencing instead of 
targeted sequencing (i.e. exome sequencing or sequencing of specific 
panels of genes) (Fratkin et al., 2012).                                                                                                                                                                                                                                                                  
In contrast to exome sequencing and the sequencing of specific panels of 
genes, the use of whole genome sequencing allows the study of both the 
non-coding and the coding regions in the human genome. The former 
comprises ~98% of the human genome, while the latter only comprises ~2% 
(Schnekenberg and Németh, 2013).   
The non-coding region was originally described as junk DNA (Orgel and 
Crick, 1980). However, the recent ENCODE project showed that a large 
proportion of the human genome is functional (Consortium, 2012). While the 
exact proportion of the genome that is functional is under debate, it is very 
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clear that some of the non-coding region is not junk DNA, and has critical 
function in terms of regulating gene expression and function across cells, 
tissues and organs (Fratkin et al., 2012; Consortium, 2012; Graur et al., 
2013). Therefore the non-coding region is now considered as a rich source 
of disease-associated SNVs that have, to date, not been properly studied, 
and for which the results of the ENCODE project could be of immense help 
in terms of developing highly precise diagnostics (Schnekenberg and 
Németh, 2013; Fratkin et al., 2012).  
1.2.1 Carrying Out Whole Genome Sequencing  
In order to carry out whole genome sequencing, the DNA must first be 
extracted from nucleated cells in a blood or tissue sample. The extracted 
DNA is then randomly fragmented in order to shorten the long DNA into 
shorter fragments. This is a key step, as the size is extremely important for 
construction of the sequencing library (which is discussed in further detail 
below). This fragmentation is normally done by physical (i.e. sonication or 
acoustic shearing), or enzymatic (digestion by DNAse 1 or Fragmentase) 
fragmentation methods. However, enzymatic methods have been found to 
produce more artefacts and therefore physical methods are preferred 
(Marine et al., 2011).  
The next step is to prepare the sequencing library. This involves, first 
performing end repair by blunting the ends of the fragments, and then, 
phosphorylating the 5’ ends using the enzymes T4 Polynucleotide kinase, T4 
DNA Polymerase and Klenow Large Fragment. The 3’ ends are then Poly A-
tailed (i.e.  stretches of adenine nucleotides are added to the 3’ ends) in 
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order to facilitate ligation to the adaptors using the enzymes Taq 
polymerase, or Klenow Fragment (Adey et al., 2010). Adaptors (short 
oligonucleotides of known sequences) are then ligated to the DNA 
fragments. These adaptors act as universal priming sites during the PCR 
amplification and sequencing stages which are discussed in more detail 
below.   All the DNA fragments are used for cluster generation (i.e. the 
conversion of the sequencing library into DNA clusters) and sequencing. 
This is in contrast to both whole-exome sequencing and sequencing of 
specific gene panels, where a physical-capture step enriches the DNA 
fragments for the entire protein coding region in the case of whole exome 
sequencing, and certain genes in the case of sequencing of specific gene 
panels (Metzker, 2009). The absence of the capture step in whole genome 
sequencing results in uniform coverage, removing any areas of low coverage 
caused by inefficient capture. This in turn reduces the average depth of 
coverage that is required for accurate SNV calling, details of which are 
discussed in section 1.2.2.4.  
Distinct clusters are then generated by spatially separating the DNA 
fragments, and then clonally amplifying them using PCR. DNA sequencing is 
then carried out. DNA can either be sequenced from one end (known as 
single end sequencing) or both ends (known as paired end sequencing). The 
latter is considered to be the better approach, as it reduces ambiguity during 
the alignment stage of the data analysis (Schnekenberg and Németh, 2013) 
(details of which are discussed further in section 1.2.2.3).   There are several 
platforms for DNA sequencing including Illumina, Roche and SOLID. While 
there are some differences in the way they operate, the basic principles are 
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identical on all platforms as shown in Figure 1.1. These basic principles are: 
four nucleotides which are fluorescently labelled are first added; if the 
nucleotide is incorporated into the DNA, a detectable signal is generated; the 
signal is then converted into a base in a process known as base calling.  
These steps are repeated over multiple cycles resulting in thousands of DNA 
fragments being analysed and sequenced (Schnekenberg and Németh, 
2013; Head et al., 2014; Natrajan and Reis-Filho, 2011).  The above steps 
for carrying out whole genome sequencing are summarised in Figure 1.2.  
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Figure 1.1: Summary of the whole genome sequencing process for Illumina 
(A),Roche (B) and SOLID (C) (Natrajan and Reis-Filho, 2011). 
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Figure 1.2: Summary of steps for carrying out whole genome sequencing  
(Schnekenberg and Németh, 2013). 
 
1.2.2 Analysing Whole Genome Sequencing Data 
The data obtained from whole genome sequencing consist of several million 
short nucleotide sequences that are about 35-400bp in length and are known 
as reads. These reads are provided by the sequencing platform in large 
(hundreds of gigabytes) text files in FASTQ format (See Appendix A).  
 
In order to call SNVs, further analyses need to be conducted on these data 
which comprise several processing steps that together comprise the 
workflow for calling SNVs from whole genome sequencing data (Altmann et 
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al., 2012; Schnekenberg and Németh, 2013; Pabinger et al., 2014). This 
workflow can be automated in many ways. This can involve writing scripts 
(either shell scripts or scripts written in a scripting language such as Perl or 
Python) or using tools such as Ruffus (Goodstadt, 2010), Bpipe (Sadedin et 
al., 2012), Biopieces (http://maasha.github.io/biopieces/), Rake 
(https://github.com/ruby/rake), SnakeMake 
(https://bitbucket.org/snakemake/snakemake/wiki/Home), Anduril (Ovaska et 
al., 2010), Taverna (http://www.taverna.org.uk/) or Galaxy (Goecks et al., 
2010).   The basic workflow is shown in Figure 1.3 and the individual steps 
are discussed in more detail in the following sections. 
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Figure 1.3: Workflow for calling SNVs from whole genome sequencing data. 
The quality control and read alignment steps are common to all techniques 
involving next generation sequencing e.g. whole genome sequencing, RNA-
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Seq, ChIP-Seq while the alignment post-processing and SNV calling steps 
are exclusive to genome resequencing (whole genome sequencing and 
exome sequencing). 
1.2.2.1 Quality Control  
The sequencing platforms are prone to errors in chemistry and 
instrumentation. Therefore the raw sequence data that are generated will 
contain sequence artefacts. These are errors in base calling, poor quality 
reads and contamination by adaptors. In order to prevent erroneous 
biological conclusions from being drawn as a result of these errors, it is 
essential to check the quality of the reads. This involves visualising the base 
quality scores and nucleotide distributions. Any errors are then removed by 
trimming the reads and/or filtering the reads based on base quality score, 
primer contamination and GC bias. This is done by using the FastQC 
package (http: //www.bioinformatics. babraham.ac.uk/projects/fastqc/) for the 
visualisation. Filtering and trimming the reads as required (Altmann et al., 
2012) is done using utilities in one of the following suites of tools: FASTX-
Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/), NGSQC (Dai et al., 2010), 
PRINSEQ (Schmieder and Edwards, 2011), SOLEXAQA (Cox et al., 2010) 
or the Biopython library (Cock et al., 2009).  These tools have various 
parameters for trimming and/or filtering the reads, which decide how many of 
the sequence artefacts are removed and therefore how much of the raw 
reads are kept.  This in turn, will determine how many of the reads are 
aligned correctly, and influence the number of SNVs called. If the 
parameters are set to trim and/or filter a high number of reads, then the 
dataset size is drastically reduced resulting in few SNVs being called. This 
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increases the chance of failing to call many true positive SNVs. If the 
parameters are set to trim and/or filter a low number of reads, then fewer 
sequence artefacts are removed, fewer reads are aligned correctly, and a 
higher number of false positive SNVs will hence be called (Yu and Sun, 
2013; Del Fabbro et al., 2013). The researcher must therefore decide the 
best trade-off between dataset size and quality, when choosing the 
parameter settings to trim and/or filter the reads. This trade-off will be based 
on the results of the visualisation of the base quality scores and nucleotide 
distributions obtained using the FastQC package (http: //www.bioinformatics. 
babraham.ac.uk/projects/fastqc/).  
1.2.2.2 Read Alignment  
After the reads have been processed to remove the sequence artefacts, they 
are aligned with the human reference genome. This involves determining the 
location within the human reference genome for a particular read which 
requires the human reference genome and an alignment tool (Pabinger et 
al., 2014; Nielsen et al., 2011).  
There are currently two sources for the human reference genome: The 
University Of Santa Cruz (UCSC) and the Genome Reference Consortium 
(GRC), both of which provide multiple human genome versions. These are 
usually the latest version and one or more older versions. Currently UCSC 
provides versions hg18, hg19 and hg38 (currently the latest release) while 
GRC provides versions GRCh37 and GRCh38 (which is currently the latest 
release). The human reference genomes present in both UCSC and GRC 
are identical (Pabinger et al., 2014). 
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A plethora of alignment tools have been developed over the past few years 
(Pabinger et al., 2014; Flicek and Birney, 2009). These include Bowtie 
(Langmead et al., 2009), Bowtie2 (Langmead and Salzberg, 2012), BWA (Li 
and Durbin, 2009), MAQ (Li et al., 2008a), SOAP (Li et al., 2008b), SOAP2 
(Li et al., 2009c), ZOOM (Lin et al., 2008a), SHRiMP (Rumble et al., 2009), 
BFAST (http://genome.ucla.edu/bfast/) and MOSAIK 
(http://bioinformatics.bc.edu/marthlab/Mosaik/). These tools follow the same 
fundamental procedure to align the reads to the human reference genome, 
and have parameters to control the number of mismatches between the 
reads and the human reference genome. These parameters also influence 
the number of SNVs called. The user is required to specify the number of 
allowed mismatches for the parameters. If the parameters are set only to 
allow perfect matches (i.e. no mismatches), then it would not be possible to 
call any SNVs as there will be no variation from the human reference 
genome. On the other hand, setting the parameters to allow a high number 
of mismatches will result in many wrongly aligned reads, and hence, result in 
the calling of a high number of false positive SNVs. Therefore, the parameter 
settings for the number of allowed mismatches between the reads and the 
human reference genome must be carefully chosen.   Therefore, a 
comprehensive evaluation of the alignment tools with the parameters set at 
varying numbers of allowed mismatches is required in order to find the 
number of mismatches that results in the lowest number of false positive 
SNVs. 
The procedure that the tools use to align the reads to the human reference 
genome exploits heuristic techniques to focus quickly on a small set of 
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locations in the human reference genome, where the best mapping is likely. 
After the identification of a smaller subset of potential mapping locations, a 
more accurate alignment algorithm such as Smith-Waterman is run on the 
smaller subset. It would be computationally infeasible to run these more 
accurate alignment algorithms to search all possible locations in the human 
genome where the reads can map. The aligned reads are stored in the 
sequence alignment/map (SAM) format (Flicek and Birney, 2009; Altmann et 
al., 2012). 
 
There are two types of heuristic alignment techniques: hash-based and the 
Burrows Wheeler Transform (BWT).  Hash-based methods are based on the 
use of a hash table data structure to scan and index the sequence data. The 
hash table is able to allow rapid access to information on the location of 
subsequences within the reference genome. The hash table can be built 
either on the set of input reads, or on the human reference genome. In the 
case of the hash table being built on the set of input reads, the reference 
genome is used to scan the hash table of reads, whereas, in the case of the 
hash table being built on the human reference genome, the set of input 
reads is used to scan the hash table of the reference genome. Tools that 
build hash tables on the reference genome have a constant memory 
requirement. However, this requirement depends on the size and complexity 
of the reference (and will be large in the case of the human reference 
genome), while tools that build hash tables on the set of input reads have 
memory requirements that are smaller and more variable, but the processing 
time to scan the entire genome can be greater if there are fewer input reads 
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(Flicek and Birney, 2009). Examples of tools that utilise the hash-based 
method by building a hash table of the input reads  are: MAQ (Li et al., 
2008a), ZOOM (Lin et al., 2008a) and SHRiMP (Rumble et al., 2009), while 
tools that build a hash table of the reference genome are: SOAP (Li et al., 
2008b), BFAST (http://genome.ucla.edu/bfast/) and MOSAIK 
(http://bioinformatics.bc.edu/marthlab/Mosaik/).  
 
Methods that make use of  BWT (Burrows and Wheeler, 1994) exploit the 
‘FM index’ data structure (Ferragina and Manzini, 2000) which enables rapid 
sub-sequence search, and, in the case of the human (and indeed all other 
mammalian genomes), is equal to, or smaller in size than, the reference 
genome itself. There are two steps involved in creating the FM index. Firstly, 
BWT is used for efficient data compression of the reference genome.  
Secondly, the final index is created. This step can be memory intensive, but 
can be done in less memory with a cost in processing time.    This final index 
is then used for rapid placement of reads on the human reference genome.  
Methods utilising BWT have a greater processing speed than methods 
utilising hash tables (Flicek and Birney, 2009; Altmann et al., 2012; 
Kärkkäinen, 2007). Examples of tools that utilise BWT are Bowtie 
(Langmead et al., 2009), Bowtie2 (Langmead and Salzberg, 2012), BWA (Li 
and Durbin, 2009) and SOAP2 (Li et al., 2009c).  
There have been some comparisons of different read aligners. These 
comparisons have all shown that there is no single best performing read 
aligner for universal use. The performance of different read aligners vary 
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depending on the type of next generation sequencing data (e.g. whole 
genome sequencing, ChIP-Seq etc.),  and the reference genome (e.g. 
human, mouse etc.). Therefore, the best read aligner is application 
dependent. (Hatem et al., 2013; Hwang et al., 2015). For example when 
aligning reads from whole genome sequencing to the human reference 
genome, the best performing read aligner is BWA, while Bowtie is the best 
performing read aligner for aligning reads from ChIP-Seq to the human 
reference genome (Hatem et al., 2013). Therefore, when choosing a read 
aligner, the researcher first must consult the published literature to see if 
there have been any performance evaluations of different read aligners for 
their particular application. If there are no such evaluations, then the 
researcher needs to evaluate the performance of a set of read aligners for 
their particular application.  
1.2.2.3 Alignment Post-Processing 
Once the reads have been aligned to the reference genome, several post- 
processing steps need to be carried out on the aligned reads before variant 
calling is carried out (Altmann et al., 2012). First, the proportion of the reads 
that were successfully aligned needs to be obtained. Next, the aligned reads 
need to be sorted according to their position in the chromosome. 
Since the PCR that is used for amplification and ligation of adaptors can 
introduce duplicated reads, these need to be removed. Some reads can 
have more than one optimal alignment: ‘non-unique alignments’; which also 
need to be removed (Altmann et al., 2012; Pabinger et al., 2014).  The 
above post-processing steps are carried out using either the SAMtools (Li et 
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al., 2009b) or Picard (http://broadinstitute.github.io/picard/) suites of tools for 
manipulating aligned reads (Altmann et al., 2012).  
Finally, reads around small indels need to be realigned to prevent calling of 
false-positive SNVs (Altmann et al., 2012). This post-processing step is 
performed by utilities in the GATK suite of tools which are a set of tools for 
analysing next-generation sequencing data (McKenna et al., 2010). There 
are no parameters that need to be set in the SAMtools, Picard or GATK 
suites of tools for the above post processing steps to be carried out (Altmann 
et al., 2012). 
1.2.2.4 SNV Calling 
After post-processing of the aligned reads, the next step is to ‘call’ SNVs. 
There are several tools available to do this from whole genome sequencing 
data. These include SAMtools (Li et al., 2009b), GATK (McKenna et al., 
2010), VarScan 2 (Koboldt et al., 2012), SNVer (Wei et al., 2011) and 
SomaticSniper (Larson et al., 2012). Some tools can call both germline and 
somatic SNVs (e.g. SAMtools and VarScan 2) while others can only call 
germline SNVs (e.g. GATK and SNVer) or somatic SNVs (e.g. 
SomaticSniper). The SNV calling tools all generate output in VCF format 
(See Appendix A).  
These tools all have parameters to control the number of SNVs called. The 
user is required to specify cutoff values for the parameters. If the parameters 
are set to very stringent cutoff values, then fewer SNVs will be called. 
However, this increases the chance of failing to call many true positive 
SNVs. If the parameters are set to very relaxed cutoff values, then a higher 
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number of SNVs will be called. However, this increases the chance of calling 
more false positive SNVs (Yu and Sun, 2013). Therefore, the cutoff values 
for the parameters for the SNV calling tools need to be carefully chosen.  
Therefore, a comprehensive evaluation of the SNV calling tools at varying 
cutoff values for the parameters is required, in order to find the cutoff value 
that calls the highest number of true positive SNVs, and the lowest number 
of false positive SNVs.  
The SNV calling step is the most important step of the variant calling 
pipeline. Therefore, the choice of SNV calling tool is vital. There have been a 
few comparisons of different SNV calling tools for human genome 
resequencing data.  
These comparisons have all shown that GATK is the best performing SNV 
calling tool. However, in order to improve the performance of the SNV calling 
process still further, the use of multiple SNV calling tools to call SNVs and 
taking the common intersection of SNVs called by these tools is 
recommended (Hwang et al., 2015; Yu and Sun, 2013; Liu et al., 2013). 
Therefore, it is necessary to evaluate different combinations of SNV calling 
tools in order to find the combination of SNV calling tools that improve the 
performance of the SNV calling process the most.  SNV calling pipelines 
would then be designed that use this combination of SNV calling tools to call 
SNVs, and take the common intersection of SNVs called by these tools. 
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1.3 Identifying the Functional Consequence of SNVs 
Once a set of SNVs have been called from whole genome sequence data 
the next step is to identify the functional consequence of the SNV. This in 
turn will enable the identification of SNVs that cause Mendelian diseases 
and act as driver SNVs in cancer. The possible functional consequences 
are:  non-synonymous, synonymous, nonsense, sense, splice site and 
transcription factor binding site (Makrythanasis and Antonarakis, 2011).  
Non-synonymous, synonymous, nonsense and sense SNVs occur only in 
the coding region. Splice site SNVs occur in the intron-exon boundary, while 
transcription factor binding site SNVs occur in both the coding and            
non-coding regions (in promoters, introns, exons and regions far upstream of 
genes (up to 10,000 bp)). 
 At the whole genome scale, it is not feasible to employ experimental 
methods to identify the functional consequence of SNVs. Therefore 
computational approaches are required to identify the functional 
consequence of SNVs. This is done by the following tools ANNOVAR (Wang 
et al., 2010), Ensembl VEP (McLaren et al., 2010) and snpEff (Cingolani et 
al., 2012). SNVs that have different functional consequences differ in terms 
of their impact on the resulting protein product.  
1.3.1 Non Synonymous SNVs 
Non-synonymous SNVs (also known as missense SNVs) are SNVs where 
one codon is replaced with another that encodes a different amino acid. 
(Read and Donnai, 2011; Khan and Vihinen, 2007). This is illustrated in 
Figure 1.4. 
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Original DNA sequence 
CATCATCATCATCATCATCAT 
Original protein sequence 
His-His-His-His-His-His-His 
Mutated DNA sequence 
CATCATCATCCTCATCATCAT 
Mutated protein sequence 
His-His-His-Pro-His-His-His 
Figure 1.4: Effect of a non-synonymous SNV. 
The impact of non-synonymous SNVs on the protein is varied.  Certain   
non-synonymous SNVs can severely damage the protein product, and alter 
its normal function, while others have a negligible effect on the normal 
function of the protein. Therefore, in addition to identifying the functional 
consequence of an SNV as being non-synonymous, its impact on the protein 
will also need to be quantified. 
 A plethora of tools have been developed to predict the impact of a               
non-synonymous SNV on protein structure and function (Khan and Vihinen, 
2007; Cline and Karchin, 2011; Pabinger et al., 2014).  These include SIFT 
(Kumar et al., 2009), PolyPhen-2 (Adzhubei et al., 2010), FATHMM (Shihab 
et al., 2013), MutationAssessor (Reva et al., 2011), SNPs3D (Yue et al., 
2006), nsSNPAnalyzer (Bao et al., 2005), SNAP (Bromberg and Rost, 2007), 
SAAPpred (Al-Numair and Martin, 2013), MutPred (Li et al., 2009a), 
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SNPS&GO (Calabrese et al., 2009) , SNPs&GO3D (Capriotti and Altman, 
2011), Panther (Thomas et al., 2003), PhD-SNP (Capriotti et al., 2006), 
PMut (Ferrer‐Costa et al., 2004), MAPP (Stone and Sidow, 2005), SusPect 
(Yates et al., 2014), Bongo (Cheng et al., 2008), Hansa (Acharya and 
Nagarajaram, 2012), Parepro (Tian et al., 2007), SNPDryad (Wong and 
Zhang, 2014),  Condel (Gonzalez-Perez and Lopez-Bigas, 2011) and 
CAROL (Lopes et al., 2012). 
Several of these tools make use of only sequence information to predict the 
impact of non-synonymous SNVs (e.g. SIFT, FATHMM, MutationAssessor, 
Panther, PhD-SNP, MAPP, SNPS&GO, Parepro and SNPDryad), while 
others make use of both sequence and structural information (e.g. 
PolyPhen-2, SNPs3D, nsSNPAnalyzer, SNAP, MutPred, SNPs&GO3D, 
PMut, SusPect, SAAPpred and Hansa). On the other hand, certain tools 
exclusively make use of structural information (e.g. Bongo). Recently, tools 
such as Condel and CAROL have been developed that exploit the 
complementarity of different tools for predicting the impact of                       
non-synonymous SNVs on protein function. These tools first obtain the 
output from several tools, and then combine the output scores of these tools 
and give the final prediction of the impact of the non-synonymous SNV.  
1.3.2 Synonymous SNVs 
Synonymous SNVs (also known as silent SNVs) are SNVs where one codon 
is replaced with another that encodes the same amino acid. Synonymous 
SNVs are conventionally assumed to have no effect on the protein and thus 
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be neutral (Read and Donnai, 2011). Therefore, no further analysis needs to 
be done after identifying an SNV as being synonymous. 
1.3.3 Nonsense SNVs 
Nonsense SNVs are SNVs where a codon is replaced with a stop codon. 
Protein synthesis then stops at that point as illustrated in Figure 1.5. If the 
SNV occurs at a location which has an exon-exon junction more than 50-55 
nucleotides upstream then nonsense-mediated decay ensues. This results in 
degradation of the mRNA transcript and complete lack of production of the 
protein product. This is equivalent to deletion of the entire gene. If a 
nonsense SNV does not trigger nonsense-mediated decay, then a truncated 
protein is produced as illustrated in Figure 1.6. Either way, nonsense SNVs 
are considered as loss-of-function SNVs (Read and Donnai, 2011; Maquat, 
2005; Kurmangaliyev et al., 2013).  Therefore, no further analysis needs to 
be done after identifying an SNV as being nonsense. 
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Original DNA sequence 
CAGCAGCAGCAGCAGCAGCAG 
Original protein sequence 
Gln-Gln-Gln-Gln-Gln-Gln-Gln 
Mutated DNA sequence 
CAGCAGCAGTAGCAGCAGCAG 
Mutated protein sequence 
Gln-Gln-Gln-Stop 
Figure 1.5: Effect of a nonsense SNV. 
 
Figure 1.6: Locations of the gene where nonsense SNVs trigger and do not trigger 
nonsense mediated decay (Maquat, 2004). 
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1.3.4 Sense SNVs  
Sense SNVs are SNVs where a stop codon is replaced with a codon that 
codes for an amino acid.  This results in the downstream 3’ Untranslated 
Region becoming part of the open reading frame which will result in a protein 
with a C-terminal extension. The mRNA transcript is hence degraded as the 
resulting protein product will be unstable. Therefore there is a complete lack 
of production of the protein product which is equivalent to complete gene 
deletion (Klauer and van Hoof, 2012).  Therefore no further analysis needs 
to be done after identifying an SNV as being sense. 
1.3.5 Splice site SNVs 
SNVs that occur in splice sites disrupt the splice sites located in the intron-
exon boundary that are required for the removal of introns and the joining of 
the exons which in turn yields the mature mRNA molecule. This results in the 
skipping of the relevant exon, or retention of intronic sequence therefore 
yielding a non-functional copy of the protein product as shown in Figure 1.7. 
Splice site SNVs are also considered as loss of function SNVs (Read and 
Donnai, 2011; Kurmangaliyev et al., 2013). Therefore no further analysis 
needs to be done after identifying an SNV as being in a splice site. 
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a) Splice site SNV causing retention of intronic sequence  
DNA 
 
 
ALTERED mRNA 
 
 
b) Splice site SNV causing exon skipping 
DNA 
 
 
ALTERED mRNA  
 
 
Figure 1.7: Effect of a splice site SNV showing a) intron retention and b) exon 
skipping.  
 
1.3.6 Transcription factor binding site SNVs 
Transcriptional regulation is key to the unique spatial and temporal 
expression of each of the 20-25,000 protein coding genes that are encoded 
in the human genome. Transcriptional regulation is mainly achieved by the 
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binding of transcription factors to their corresponding TFBSs. The TFBSs 
that correspond to a particular transcription factor can be found in promoters, 
introns, exons and regions far upstream of genes (up to 10,000 bp).  In many 
cases, transcriptional regulation is achieved by combinations of transcription 
factors binding cooperatively to their corresponding TFBSs. This 
phenomenon is known as combinatorial control. The stretch of DNA 
sequence containing the TFBSs for a set of transcription factors that bind 
cooperatively is known as a Cis Regulatory Module (CRM). (Narlikar and 
Ovcharenko, 2009; Maston et al., 2006; Hardison and Taylor, 2012; 
Suryamohan and Halfon, 2015).  
SNVs that occur in TFBSs can disrupt the key protein-DNA interactions 
required for binding of transcription factors to their corresponding TFBSs 
which regulate transcription as shown in Figure 1.8. Gene expression of the 
corresponding gene is therefore altered. Consequently, the mRNA and 
hence protein levels, are altered (Worsley-Hunt et al., 2011; de Vooght et al., 
2009).  However, this is now thought only to be the consequence of SNVs 
occurring in TFBSs in the non-coding regions as questions have been raised 
as to whether TFBSs in protein coding regions are functional in terms of 
regulation of gene expression (Xing and He, 2015). In order to identify SNVs 
that occur in TFBSs, a set of TFBSs are required.  
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Figure 1.8: Effect of an SNV in a transcription factor binding site. 
 
 
1.4 Experimental Identification of Transcription 
Factor Binding Sites 
There are many experimental techniques that have been used to identify 
TFBSs. These are reviewed briefly below.   
Traditionally, the Electro-Mobility Shift Assay (EMSA) (Garner and Revzin, 
1981) has been the de facto technique for experimentally identifying TFBSs. 
EMSA is carried out by subjecting mixtures of protein and nucleic acid to 
electrophoresis, and then using autoradiography to determine the distribution 
of nucleic acid mixtures.  EMSA works by exploiting the ability of a non-
denaturing polyacrylamide gel to act as a molecular sieve, hence separating 
the protein-bound DNA from the unbound DNA. The protein-nucleic acid 
complexes migrate more slowly than the free nucleic acid (Hellman and 
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Fried, 2007; Elnitski et al., 2006). The EMSA assay is summarised in Figure 
1.9. 
 
Figure 1.9: The EMSA assay  (Yang, 1998). Electrophoresis is carried out on 
mixtures of protein and 32P labelled nucleic acid. This is followed by 
autoradiography. The unbound DNA separates from the protein-nucleic acid 
complexes by migrating faster on the gel.      
 
45 
 
  An alternative technique is the DNase I footprinting/protection assay which 
combines the cleavage reaction of DNase I with the binding properties of the 
EMSA assay  (Galas and Schmitz, 1978). The fundamental principle of the 
DNase I footprinting/protection assay is that the bound protein protects the 
phosphodiester backbone of the DNA from hydrolysis by DNase I. Following 
hydrolysis by DNase I, the resulting fragments undergo electrophoresis and 
are visualised by autoradiography. Any TFBSs that are cleavage-protected 
will appear as a blank image in the semicontinuous ladder of nucleotide 
positions (Brenowitz et al., 2001; Elnitski et al., 2006).  The DNase I 
footprinting/protection assay is summarised in Figure 1.10. 
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Figure 1.10: The DNase I footprinting/protection assay.  The labelled DNA is 
hydrolysed by DNase I and the resulting fragments undergo electrophoresis and are 
visualised by autoradiography. Areas of the DNA bound by protein are protected 
from hydrolysis and appear as blank images.  
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A key problem with both the EMSA and DNase I footprinting/protection 
assays is the identification of unwanted protein-DNA interactions that result 
from the interference of non-specific DNA binding proteins such as DNA 
repair proteins (Elnitski et al., 2006).  
 
A more technically advanced assay is the  ‘Systematic Evolution of Ligands 
by EXponential enrichment’ (SELEX) assay (Tuerk and Gold, 1990). SELEX 
is used to select dsDNAs that are bound specifically by a particular 
transcription factor from a random library. It works by screening a large pool 
of short, random oligonucleotide probes which are recognized by a protein of 
interest (Tuerk and Gold, 1990). The oligonucleotides that are bound by the 
protein of interest are then separated from the oligonucleotides that are not 
bound in a step known as selection. The oligonucleotides that were bound 
by the target protein are then amplified by PCR. This process of screening, 
selection and PCR amplification is termed a SELEX ‘round’. Multiple rounds 
of SELEX are performed (Tuerk and Gold, 1990; Djordjevic, 2007). The 
SELEX protocol is summarised in Figure 1.11. 
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Figure 1.11: The SELEX assay.  SELEX consists of multiple rounds. A SELEX 
round consists of screening a large pool of short nucleotide probes that are 
recognised by the protein of interest. Oligonucleotides that are bound to protein are 
separated from oligonucleotides that are free. PCR amplification of the protein-
bound oligonucleotides then follows.     
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1.5 Experimental Identification of Genome Wide 
Transcription Factor Binding Events 
There is now an opportunity to identify and characterize protein-DNA binding 
events at a genome-wide level through the use of the techniques ChIP-chip 
and ChIP-Seq. ChIP-chip and ChIP-Seq are high throughput versions of the 
Chromatin ImmunoPrecipitation (ChIP) assay. 
In a ChIP assay, the DNA-binding protein of interest is cross-linked to the 
DNA using formaldehyde, hence capturing the protein-DNA interactions in 
vivo. The DNA is then fragmented into small fragments of around 200–1000 
bp, and an antibody specific for a given transcription factor is then used to 
immunoprecipitate the DNA-protein complex. The cross-links are then 
reversed, releasing the DNA for PCR amplification (Elnitski et al., 2006). 
However, the ChIP assay has the inability to detect the precise binding sites 
(that are between 9 and 15 bp long) within the identified regions. The ChIP 
assay is summarised in Figure 1.12. 
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Figure 1.12: The ChIP assay.  Formaldehyde is used to cross-link a DNA binding 
protein to the DNA. The DNA is then fragmented and the DNA-protein complex is 
immunoprecipitated. The cross-links are reversed and the DNA undergoes PCR 
amplification.  
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ChIP-chip involves labelling the resulting fragments from the ChIP assay  
with a fluorescent molecule (e.g. Cy5 or Alexa 647) followed by hybridization 
to genomic tiling microarrays (Ren et al., 2000). The labelling and 
hybridization steps are similar to cDNA microarrays (Ren et al., 2000; Buck 
and Lieb, 2004). The ChIP-chip experiment is summarised in Figure 1.13. 
ChIP-Seq involves performing end repair, poly-A tailing and then the ligation 
of adaptors to the resulting DNA fragments from the ChIP assay. Clusters of 
these fragments are then generated. Massively parallel sequencing is then 
carried out (Park, 2009). These steps are similar to other next generation 
sequencing experiments such as whole genome or RNA sequencing. The 
ChIP-Seq experiment is summarised in Figure 1.14.  
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Figure 1.13: The ChIP-ChIP workflow (Ren et al., 2000). The resulting fragments 
from the ChIP assay are labelled with a fluorescent molecule and then hybridised to 
a microarray.    
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Figure 1.14:  The ChIP-Seq Workflow  (Park, 2009). End repair, poly-A tailing and 
adaptor ligation is carried out on the DNA fragments resulting from the ChIP assay. 
Clusters of fragments are then generated which are then subject to massively 
parallel sequencing. 
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There are a number of advantages of using ChIP-Seq instead of ChIP-chip 
to identify transcription factor binding regions. A key improvement over ChIP-
chip is in base pair resolution given that arrays have limitations in resolution 
arising from uncertainties in the hybridization step which can also introduce 
noise from cross hybridization between sequences that are not perfectly 
matched. This arises owing to the inherent complexity of nucleic acid 
hybridization, and the fact that it depends on multiple factors such as GC 
content, length, concentration, secondary structure of the target and probe 
sequences (Park, 2009). In addition, the intensity signal measured on arrays 
suffers from non-linearity over its range (Park, 2009) and the dynamic range 
can also be limited such that the signal is below the sensitivity threshold or 
above the saturation point. The result is that biologically relevant peaks 
which are identified in ChIP-Seq are obscured when ChIP-chip is employed. 
In addition, ChIP-Seq allows repetitive regions to be analysed which are 
normally obscured on arrays. This is facilitated by the fact that genomic 
coverage is not limited to the probe sequences that have been fixed on the 
array in the ChIP-chip approach. Hence ChIP-Seq has a higher specificity 
and sensitivity compared with ChIP-chip (Park, 2009; Joshua et al., 2011), 
and has largely superseded the ChIP-chip method. ChIP-Seq is now the 
current gold standard for identifying protein/DNA interaction regions such as 
transcription factor binding regions (Adli and Bernstein, 2011). 
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1.6 Challenges in Identifying SNVs in Transcription 
Factor Binding Sites 
Unfortunately the number of precise experimentally characterised TFBSs is 
very limited. This is because the techniques that experimentally identify 
precise TFBSs (EMSA, DNase I footprinting/protection and SELEX assays) 
are low-throughput and hence are only able to characterize a small number 
of protein-DNA binding events. However, the recent ENCODE project 
(Consortium, 2012) has resulted in a large amount of ChIP-Seq data being 
publicly available. Therefore, for many transcription factors, whole genome 
maps of transcription factor binding exist. However, as the binding regions 
identified by these ChIP-Seq experiments are much longer than the binding 
site for a particular transcription factor, the precise TFBS within a region 
identified by ChIP-Seq still needs to be detected. Given that the number of 
experimentally characterised TFBSs are limited, the detection of the precise 
TFBS within a ChIP-Seq region is completely reliant on computational 
prediction of TFBSs. The computational prediction of TFBSs is generally 
performed by using a pattern matching tool to scan ChIP-Seq regions with a 
Position Weight Matrix (PWM) which describes a transcription factor of 
interest.  Improving the computational prediction of TFBSs will aid the 
identification and interpretation of SNVs in TFBSs from whole genome 
sequencing data (Worsley-Hunt et al., 2011; Consortium, 2012; Fratkin et al., 
2012; Hunt et al., 2014; Bailey and Machanick, 2012). 
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1.7 Aims and Outline of Thesis 
This thesis will focus on predicting TFBSs computationally, and, then 
exploiting the resulting predicted TFBSs to analyse and interpret the effects 
of somatic cancer driver and passenger SNVs in TFBSs. 
Chapter 2 discusses the evaluation of the performance of a set of pattern 
matching tools that can be locally installed, and the identification of the best 
performing tool. Chapter 3 discusses the evaluation of a set of motif 
discovery tools that are used to derive PWMs, the identification of the best 
performing tool, the use of this tool to generate a set of new PWMs, and by 
finally checking that the selection of the best pattern matching tool is not 
unduly influenced by the choice of PWMs. Chapter 4 discusses the 
application of the analyses in chapters 2 and 3 to the problem of analysing 
the conservation of the positions of somatic cancer driver and passenger 
SNVs in TFBSs, and using the results of the analysis to help prioritize 
somatic cancer driver SNVs in TFBSs. Chapter 5 discusses the further 
analysis of the large datasets of somatic cancer driver and passenger SNVs 
collected in chapter 4.  Chapter 6 provides a summary of the major findings 
in this thesis and discusses future work. 
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2 An Independent Assessment of 
Pattern Matching Tools 
 
The work presented in this chapter has been published in BMC 
Bioinformatics (Jayaram, N., Usvyat, D. and Martin, A.C.R. “Evaluating tools 
for transcription factor binding site prediction”, BMC Bioinformatics, in press). 
DOI: 10.1186/s12859-016-1298-9 
 
The aim of this chapter is to conduct an independent assessment of a set of 
pattern matching tools which can be installed locally, and therefore, be used 
for bulk analysis. This assessment will evaluate the performance of pattern 
matching tools that predict individual TFBSs and pattern matching tools that 
predict clusters of TFBSs.  
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2.1 Introduction 
2.1.1 Pattern Matching Tools  
 
Pattern matching tools are a key component of TFBS prediction. Pattern 
matching tools fall into two classes: those that predict individual TFBSs and 
those that predict clusters of TFBSs.  
Pattern matching tools predict putative individual TFBSs or clusters of 
TFBSs by utilising prior knowledge of the experimentally determined TFBSs 
describing a transcription factor of interest. These experimentally-determined 
TFBSs must be represented either as a consensus sequence, or as a PWM 
(Sand et al., 2008; Elnitski et al., 2006).  
 A consensus sequence consists of the most frequent base at each position 
of the experimentally determined TFBS. This consensus sequence can 
either be strict (using only the 4 letters A, C, G and T from the International 
Union of Pure and Applied Chemistry (IUPAC) nucleotide code) or 
degenerate (using the complete 15 letter IUPAC nucleotide code). The 
complete IUPAC nucleotide code is shown in Table 2.1.  
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Nucleotide Code Base 
A  Adenine 
C Cytosine 
G Guanine 
T Thymine 
R Adenine or Guanine 
Y Cytosine or Thymine 
S Guanine or Cytosine 
W Adenine or Thymine 
K Guanine or Thymine 
M Adenine or Cytosine 
B Cytosine or Guanine or Thymine 
D Adenine or Guanine or Thymine 
H Adenine or Cytosine or Thymine 
V Adenine or Cytosine or Guanine 
N Any Base 
 
Table 2.1: The complete IUPAC nucleotide code 
 
Use of the strict consensus sequence fails to take important variable regions 
into account as certain positions within the consensus sequence may consist 
of nucleotides with equivalent frequencies, therefore, resulting in a more 
complex pattern. The use of the strict consensus sequence can therefore 
exclude a subset of the binding site repertoire.   Degenerate consensus 
sequences take into account the occurrence of alternative nucleotides at a 
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particular position in the TFBS. The use of degenerate consensus 
sequences characterises the diversity of the TFBS repertoire, and alleviates 
many of the problems associated with the use of the strict consensus 
sequence. However, degenerate forms of the consensus sequence fail to 
take into account the relative frequencies of the alternative nucleotides 
(Elnitski et al., 2006; Nguyen and Androulakis, 2009; Turatsinze et al., 2008).  
The use of PWMs has proven to be very successful in various problems in 
DNA and protein sequence analysis, and is currently the de facto model for 
TFBS prediction. The PWM model is a matrix of scores which correspond to 
the frequencies of the four nucleotides at each position in the TFBS motif.    
In contrast, to the consensus model, the PWM model therefore takes into 
account the preference for each of the four nucleotides. PWMs can then be 
visualised as a sequence logo. The fundamental assumption of the PWM 
model is that the bases at the different positions of the TFBS motif are 
statistically independent (Nguyen and Androulakis, 2009; Elnitski et al., 
2006). 
These different ways of representing experimentally determined TFBSs are 
summarised in Figure 2.1. 
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Figure 2.1: Different ways of representing a set of experimentally determined 
TFBSs  (left) including consensus sequences (bottom left),PWMs (top right) and 
sequence logos( bottom right) (Zambelli et al., 2012). 
 
The pattern matching tools use PWMs to predict TFBSs by scanning a DNA 
sequence of interest with the PWM for a transcription factor of interest. Only 
one PWM at a time can be used to scan the DNA sequence by the pattern 
matching tools currently available.  The pattern matching tools that predict 
individual TFBSs scan the DNA sequence in segments which are the same 
length as the PWM. A raw score or a p-value is calculated to quantify the 
extent of similarity of the sequence segment to the PWM. The sequence 
segments which have scores or p-values that exceed a predefined threshold 
are reported as putative TFBSs (Hannenhalli, 2008; Turatsinze et al., 2008).  
The pattern matching tools that predict clusters of TFBSs predict the TFBSs 
by first scanning the DNA sequence in segments that are the same length as 
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the PWM. A cluster is defined as a region of DNA that has a high density of 
predicted TFBSs for a particular transcription factor. The density of a region 
of DNA in predicted TFBSs is quantified by a raw score or p-value. The 
regions of DNA that have scores or p-values that exceed a particular 
threshold are reported as putative clusters of TFBSs (Turatsinze et al., 
2008). 
The problem with the naïve use of pattern matching tools is that the TFBSs 
are inherently short and degenerate which can result in a high error rate. 
There is therefore a need to evaluate the performance of these pattern 
matching tools in order to improve TFBS prediction (Hannenhalli, 2008; 
Turatsinze et al., 2008).  
 
2.1.2 Evaluating the Performance of Pattern Matching Tools 
In order to conduct an evaluation of pattern matching tools, careful choices 
need to be made regarding the positive and negative controls and the source 
of the PWMs used in the evaluation. These are discussed further in the 
following two sections.   
2.1.3    Choice of Positive and Negative Control Sets 
Evaluating the performance of pattern matching tools requires positive and 
negative control sets.   
The aim of the positive control is to enable the assessment of performance 
through calculation of standard performance measures such as sensitivity 
and positive predictive value. The positive control takes the form of a set of 
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experimentally characterised TFBSs together with their corresponding gene 
sequences (Sand et al., 2008).  
Experimentally validated precise TFBSs are available either from the 
commercial TRANSFAC resource, or from the open access resources 
PAZAR (Portales-Casamar et al., 2009) and ORegAnno (Griffith et al., 
2008). Availability and application of the data from TRANSFAC is restricted 
by a commercial license. Hence, TRANSFAC was rejected for the analyses 
in this thesis. The data in PAZAR are a superset of ORegAnno, making 
PAZAR the most comprehensive open access resource. Hence PAZAR has 
been chosen as the source of the experimentally characterised TFBSs used 
in the work described in this thesis. PAZAR contains TFBSs for a total of 73 
human transcription factors that correspond to a total of 865 unique human 
genes. 
The purpose of the negative control is to assess the false positive rate of a 
pattern matching tool. The negative control can take the form of artificially 
generated sequences or randomized gene sequences corresponding to the 
genome of interest. The problem with using artificially generated sequences 
is that such sequences are generated using a theoretical background model 
(e.g. Bernoulli or Markov) which may not reflect the complexity of the 
genome of interest. Any results obtained can be overly optimistic i.e. result in 
no TFBSs being predicted by any pattern matching tools and therefore failing 
to discriminate between pattern matching tools in terms of their false positive 
rate. This can especially be a problem where vertebrate genomes are 
concerned given their high level of complexity (Sand et al., 2008). The use of 
randomized gene sequences relevant to the genome of interest will be more 
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stringent in terms of the results obtained (Sand et al., 2008).  Hence, 
randomized human gene sequences were chosen to act as the negative 
control for the work described in this thesis.  
2.1.4 Choice of PWM Resource 
 
There are two main resources for obtaining PWMs. These are the 
commercial resource TRANSFAC, and the open access resource JASPAR. 
The TRANSFAC resource was established in 1988 and has since been 
regularly updated.  The JASPAR resource was established in 2004 
(Sandelin et al., 2004) and has had five further updates. The updates for 
JASPAR were in 2006 (Vlieghe et al., 2006), 2008 (Bryne et al., 2008), 2010 
(Portales-Casamar et al., 2010), 2014 (Mathelier et al., 2013) and 2016 
(Mathelier et al., 2015a).  
Recently three new open access resources have been established: 
HOCOMOCO (Kulakovskiy et al., 2013b), HOMER (Heinz et al., 2010), 
(http://homer.salk.edu/homer/motif/HomerMotifDB/homerResults.html) and 
CIS-BP (Weirauch et al., 2014). The CIS-BP resource is somewhat different 
from the other PWM resources; rather than primarily focussing on including 
newly derived PWMs, the objective is to collate all pre-existing PWMs from 
existing open-source resources and individual publications and contains 
some redundancy (i.e. multiple PWMs for a particular transcription factor) 
(Weirauch et al., 2014).  
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For the work described in this chapter, the JASPAR resource was chosen to 
be the source of the PWMs as it is a well-respected freely-available resource 
that has been available for a long time and is widely used.  
 
2.1.5 Selection of Pattern Matching Tools 
 
A number of pattern matching tools that predict individual TFBSs and 
clusters of TFBSs have been developed. These pattern matching tools are 
available in two forms: online and locally-installable. The online forms of the 
pattern matching tools are only capable of predicting TFBSs for a rather 
limited number of DNA sequences. Therefore, in order to perform any bulk 
analysis (e.g. predicting TFBSs within regions identified by ChIP-Seq),   the 
locally-installable forms of the pattern matching tools need to be used. The 
pattern matching tools that predict individual TFBSs which have a locally- 
installable version are the open source tools FIMO (Grant et al., 2011), 
Patser (Turatsinze et al., 2008), Clover (Frith et al., 2004a), PoSSuMsearch 
(Beckstette et al., 2006) and matrix-scan (Turatsinze et al., 2008), and the 
commercial tools Match (Kel et al., 2003) and Patch (Matys et al., 2006). The 
pattern matching tools that predict clusters of TFBSs, and have a locally- 
installable version are the open source tools MCAST (Bailey and Noble, 
2003), BayCis (Lin et al., 2008b), Cister (Frith et al., 2001), Cluster-Buster 
(Frith et al., 2003), Comet (Frith et al., 2002) and the commercial tool 
Matrixcatch (Matys et al., 2006).   
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 All of the above pattern matching tools require a set of DNA sequences in 
FASTA format and PWMs as input and produce a list of putative TFBS 
clusters, or individual TFBSs, as output. The putative TFBS clusters or 
individual TFBSs are produced as plain text. Each pattern matching tool 
requires the PWM to be in a particular file format which differs between 
different pattern matching tools (See Appendix A).  
In this evaluation, the decision was taken to use only the pattern matching 
tools listed above which are open source. Therefore, the pattern matching 
tools that predict clusters of TFBSs that were chosen for this evaluation were 
MCAST (Bailey and Noble, 2003), BayCis (Lin et al., 2008b), Cister (Frith et 
al., 2001), Cluster-Buster (Frith et al., 2003) and Comet (Frith et al., 2002). 
The pattern matching tools that predict individual TFBSs chosen were FIMO 
(Grant et al., 2011), Patser (Turatsinze et al., 2008), Clover (Frith et al., 
2004a), PoSSuMsearch (Beckstette et al., 2006) and matrix-scan 
(Turatsinze et al., 2008).   
 
Table 2.2 describes the pattern matching tools considered in this evaluation 
and summarises their required PWM formats (see Appendix section A.4) and 
provides the URLs for downloading the pattern matching tools together with 
the relevant citations. 
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Table 2.2: Description of the pattern matching tools chosen for evaluation, their 
required PWM formats, URLs for downloading the tools and the relevant citations. 
 
 
Tool PWM Format URL  And Citation                                       Description
MCAST MEME http://meme-suite.org/ 
(Bailey and Noble, 2003) 
Uses motif-based HMM to 
predict clusters  
BayCis tab http://www.sailing.cs.cmu.
edu 
(Lin et al., 2008b) 
Uses  Bayesian 
hierarchical HMM to 
predict clusters  
Cister Cluster-Buster http://zlab.bu.edu 
(Frith et al., 2001) 
Uses HMM to predict 
clusters  
Cluster-Buster Cluster-Buster http://zlab.bu.edu 
(Frith et al., 2003) 
Uses motif based model 
to predict clusters 
Comet Cluster-Buster http://zlab.bu.edu 
(Frith et al., 2002) 
Predicts clusters by 
subtracting linear gap 
penalty from  PWM 
scores 
FIMO MEME http://meme-suite.org/ 
(Grant et al., 2011) 
Predicts TFBSs by 
scanning DNA with PWM 
Patser tab http://www.rsat.eu/ 
(Turatsinze et al., 2008) 
Predicts TFBSs by 
scanning DNA with PWM 
Clover Cluster-Buster http://zlab.bu.edu 
(Frith et al., 2004a) 
Predicts TFBSs by 
scanning DNA with PWM 
PoSSuMsearch PoSSuM-PSSM http://bibiserv.uni- de/ 
(Beckstette et al., 2006) 
Predicts  TFBSs by 
scanning DNA with PWM 
matrix-scan MEME/Cluster-
Buster/TRANSFAC/
JASPAR 
http://www.rsat.eu/ 
(Turatsinze et al., 2008) 
Predicts TFBSs by 
scanning DNA with PWM 
68 
 
2.1.6 Details of the selected pattern matching tools 
2.1.6.1 MCAST  
MCAST uses a motif-based hidden markov model (HMM) with the Viterbi 
distance (Viterbi, 1967) applied to it to predict clusters of TFBSs. The HMM 
is non-conventional in that the transition costs are arbitrary instead of being 
the logarithms of the transition probabilities. The HMM is created from the 
query motifs, and their reverse complements. A score is calculated for each 
predicted cluster to quantify its density in predicted TFBSs. This score is the 
sum of the scores of the hits (putative TFBSs), gaps (positions within 
clusters not aligned with motifs), and inter-cluster regions (positions between 
clusters). This score is then converted into an E-value (Bailey and Noble, 
2003).    
2.1.6.2 BayCis 
BayCis uses a Bayesian hierarchical HMM to predict clusters of TFBSs. The 
Bayesian hierarchical HMM is a variation of the classical HMM where the 
hidden states are not equal.  The architecture of the Bayesian hierarchical 
HMM has been constructed to encode a set of rules according to the 
developer’s expectation regarding the organisation of cis-regulatory regions. 
This expectation is that a cis-regulatory region is basically a sequence of 
motifs. A maximum a posteriori (MAP) score is calculated for each predicted 
cluster to quantify its density in predicted TFBSs. This score is based on the 
posterior probabilities of the labelling state at each site (Lin et al., 2008b).  
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2.1.6.3 Cister 
Cister uses a HMM to predict clusters of TFBSs. The HMM’s architecture 
and transition probabilities represent the developer’s assumption regarding 
the distribution of clusters. This assumption is that occasional clusters of 
TFBSs occur within a large amount of DNA sequence.   A score is calculated 
for each predicted cluster to quantify its density in predicted TFBSs. This 
score is the probability that a segment of DNA is a cluster of TFBSs (Frith et 
al., 2001).  
2.1.6.4 Cluster-Buster 
Cluster-Buster uses a motif cluster model to predict clusters of TFBSs. This 
model assumes that motif clusters occur randomly with a uniform 
distribution. A log-likelihood ratio score is calculated for each predicted 
cluster to quantify its density in predicted TFBSs. (Frith et al., 2003).  
2.1.6.5 Comet  
Comet predicts clusters of TFBSs by summing PWM scores and subtracting 
a linear ‘gap penalty’ that corresponds to the spacer sequences between 
motifs. A log likelihood ratio score is then calculated for each predicted 
cluster to quantify its density in predicted TFBSs. This log likelihood ratio 
score is then converted into an E value (Frith et al., 2002).    
2.1.6.6 FIMO 
FIMO predicts individual TFBSs by scanning a DNA sequence with a PWM. 
A log-likelihood ratio score is then calculated to quantify the extent of 
similarity of each predicted TFBS to the PWM which is then converted to a p-
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value using dynamic programming assuming a zero order null model where 
sequences are generated at random (Grant et al., 2011).  
2.1.6.7 Patser  
Patser predicts individual TFBSs by scanning a DNA sequence with a PWM. 
It then calculates a score to quantify the extent of similarity of each predicted 
TFBS to the PWM. This score is obtained by multiplying the scores for each 
nucleotide column in the PWM. These scores are converted to integers 
which are then converted to p-values by calculating the probability of 
observing a particular minimum integer at a particular sequence position 
(Turatsinze et al., 2008). 
2.1.6.8 Clover 
Clover predicts individual TFBSs by scanning a DNA sequence with a PWM. 
It then calculates an average likelihood score to quantify the extent of 
similarity of each predicted TFBS to the PWM. These raw scores are then 
converted to p-values. This is done by randomly shuffling the nucleotides 
within each sequence, and calculating the motif’s raw score for the shuffled 
sequences. This step is repeated multiple times. The fraction of times that 
the randomized raw score exceeds the real raw score becomes the p-value  
(Frith et al., 2004a). 
2.1.6.9 PoSSuMsearch 
PoSSuMsearch predicts individual TFBSs by scanning a DNA sequence with 
a PWM. It then calculates a score to quantify the extent of similarity of each 
predicted TFBS to the PWM. This is done by multiplying the scores for each 
nucleotide column in the PWM. It employs a lazy evaluation algorithm to 
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convert the scores into p-values. The lazy evaluation algorithm only uses a 
small fraction of the score distribution (Beckstette et al., 2006).  
2.1.6.10 matrix-scan   
matrix-scan predicts individual TFBSs by scanning a DNA sequence with a 
PWM. It then calculates a weight score to quantify the extent of similarity of 
each predicted TFBS to the PWM. This weight score is obtained by 
computing the log-ratio of two probabilities. These are the probability of the 
predicted TFBS to occur according to the PWM, and the probability of the 
predicted TFBS to occur according to the Markov chain-based background 
model. These weight scores are then converted to p-values by generating 
the distribution of all possible weight scores and calculating the probability of 
obtaining a particular score at random (Turatsinze et al., 2008). 
 
 
2.2 Methods 
All software was locally installed. 
There are only 15 human transcription factors which both have PWMs in JASPAR 
and experimentally characterised binding sites in PAZAR as shown in Figure 2.2. 
These are BRCA1, E2F1, ELK4, ESR1, ESR2, GATA2, GATA3, IRF1, MAX, NFKB, 
STAT1, YY1, CTCF, NF-YA and SP1.  Hence, the performance of the pattern 
matching tools could only be assessed for these 15 transcription factors.  
Table 2.3 summarises the biological function of these 15 transcription 
factors.  
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Figure 2.2: Venn diagram showing the overlap between the PWMs in JASPAR.2010 
and the experimentally characterised TFBSs in PAZAR 
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Table 2.3: Biological function of the 15 human transcription factors for which 
performance was assessed. 
 
The PWMs for the 15 human transcription factors were obtained from  the 
2010 release of JASPAR (JASPAR.2010) (Portales-Casamar et al., 2010), 
as this was the latest available release at the time this work was carried out. 
These PWMs are derived from SELEX, or individual promoter assays, and 
were in the JASPAR format. 
 
Transcription Factor Biological Function 
BRCA1 regulation of DNA damage repair and immune response 
genes  
E2F1 regulation of cell cycle, and metabolic pathway genes  
ELK4 regulation of cell cycle and immune response genes  
ESR1 regulation of cell cycle genes  
ESR2 regulation of cell cycle genes  
GATA2 regulation of cell cycle and T-cell receptor genes 
GATA3 regulation of cell cycle and T-cell receptor genes  
IRF1 regulation of cell cycle, apoptosis and tumour suppression 
genes 
MAX regulation of cell cycle, and metabolic pathway genes 
NFKB regulation of genes involved in several key cellular processes 
STAT1 regulation of macrophage activation and tumour surveillance 
genes  
YY1 regulation of genes involved in several key cellular processes 
CTCF regulation of genes involved in several key cellular processes 
NF-YA regulation of Proteasome genes 
SP1 regulation of genes involved in several key cellular processes  
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Of all the tools chosen for evaluation, only matrix-scan can accept the 
JASPAR format. For the remainder of the pattern matching tools, these 
PWMs were converted from the JASPAR format into the formats required for 
the particular pattern matching tool using the convert-matrix program from 
the RSAT suite (Thomas-Chollier et al., 2011)  to generate Cluster-Buster 
and the tab formats, and the jaspar2meme program, from  MEME-SUITE 
(Bailey et al., 2015) to generate the MEME format. There is no single 
program capable of converting the JASPAR format to the PoSSuM-PSSM 
format, so the convert-matrix program was used to convert the PWMs from 
JASPAR to TRANSFAC format and then the transfac2gen program (which is 
included with the PoSSuMsearch download) was used to convert the PWMs 
from TRANSFAC to PoSSuM-PSSM format. 
 
2.2.1 Evaluating Performance 
Known precise TFBSs, experimentally characterized from biochemical 
protein-DNA binding experiments, corresponding to the 15 human 
transcription factors, were downloaded from PAZAR in GFF format 
(Portales-Casamar et al., 2009), for a total of 181 human genes.  
 
PAZAR contains some redundancy (multiple instances of the same TFBS 
annotated for a given gene at the same location), so, any duplicated TFBSs 
were removed using the UNIX command uniq. Subsets of this dataset were 
then selected, which contained at least one TFBS for the transcription factor 
being evaluated in a particular comparison. The GFF file was then converted 
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into BED format using the GFF-to-BED conversion utility in Galaxy (Goecks 
et al., 2010).  
 
TFBSs can occur in the promoter region, and in introns and exons, as well 
as far upstream of genes (up to 10,000 bp) (Farnham, 2009; Cline and 
Karchin, 2011). Consequently, the complete gene sequence (i.e. both exons 
and introns), together with an upstream region of 10,000 bp of each of the 
181 genes was obtained in FASTA format. In addition, the genomic 
coordinates of these sequences were obtained as a text file. The DNA 
sequences and genomic coordinates were obtained from Biomart (Smedley 
et al., 2009) using the biomaRt package in Bioconductor (Durinck et al., 
2005; Durinck et al., 2009; Gentleman et al., 2004). The genomic 
coordinates were converted to BED format using Pybedtools (Dale et al., 
2011).  
Prediction of TFBSs was carried out using the selected pattern matching 
tools together with the PWMs using the DNA sequences obtained from 
Biomart.   The pattern matching tools were run at their default cutoff 
thresholds, as this is normal practice in order to minimise the false positives 
and false negatives while maximising the true positives (Sand et al., 2008; 
Turatsinze et al., 2008). All of the resulting text files containing the predicted 
TFBSs were converted to BED format using Pybedtools (Dale et al., 2011).  
The coordinates of the predicted TFBSs from all of the selected pattern 
matching tools are relative to their larger genomic fragments (i.e. they are 
relative coordinates). The coordinates of the experimentally characterised 
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TFBSs obtained from PAZAR are genomic coordinates (i.e. describing their 
actual location in the genome). In order to compare the predicted TFBSs and 
the known TFBSs, the coordinates of the predicted TFBSs were converted 
from relative to genomic coordinates, using the convert-feature program from 
RSAT (Thomas-Chollier et al., 2011) with output in BED format.   The 
genomic coordinates of DNA sequences obtained previously, were provided 
as the source of genomic coordinates to the convert-feature program. The 
convert-feature program requires all input files in BED format, so both the 
coordinates of the predicted TFBSs and the coordinates of the DNA 
sequences obtained from Biomart were first converted to BED format.   
The predicted TFBSs were compared with the experimentally characterised 
TFBSs, using the intersectBed program from the BEDTools suite (Quinlan 
and Hall, 2010), which requires all input files to be in BED format. Hence the 
reason for converting the coordinates of the experimentally characterised 
TFBSs obtained from PAZAR to BED format. 
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True positives were defined as predicted binding sites having a minimum 
overlap of 70% of base pairs with known binding sites from PAZAR. 
Similarly, false positives were defined as predicted binding sites not having 
an overlap of at least 70% of base pairs with a known binding site, and false 
negatives were defined as known binding sites that were not identified. The 
overlap of 70% in the context of the evaluation of performance of pattern 
matching tools is a practice that has been recommended by Sand et al. 
(2008). Obtaining a true estimate of the total number of negative sites (and 
hence the number of true negatives) is hard due to the ambiguities that exist 
in defining negative sites that are neither experimentally characterised nor 
computationally predicted. Therefore the normal practice of avoiding 
performance measures that require true negative counts was adopted (Sand 
et al., 2008). This comparison of the experimentally characterised TFBSs 
with the predicted TFBSs is shown in Figure 2.3. 
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Figure 2.3: A schematic illustration of the comparison between known and predicted 
TFBSs which are represented by blocks. The dark green blocks represent the 
known TFBSs,  the blue blocks represent the predicted TFBSs, the light green 
blocks represent true positives, the red blocks represent false positives and the 
orange blocks represent false negatives (Sand et al., 2008). 
For pattern matching tools that predict clusters of TFBSs, all predicted 
component TFBSs within a region were required to overlap with 
experimentally characterised sites, by a minimum of 70% of base pairs, for a 
prediction to be regarded as a true positive. 
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Performance was assessed by calculating sensitivity, positive predictive 
value and geometric accuracy. These were averaged across the 
transcription factors and genes analysed.  
 
The sensitivity (Sn) describes the fraction of the experimentally 
characterised TFBSs that are covered by the predicted TFBSs which is 
calculated as    
𝑆𝑆𝑆𝑆 =  𝑇𝑇𝑇𝑇(𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹)   ( 2. 1) 
 
Where 𝑇𝑇𝑇𝑇 is the number of true positives and 𝐹𝐹𝐹𝐹 is the number of false 
negatives. 
The positive predictive value (PPV) describes the fraction of the predicted 
TFBSs that are also found in the set of experimentally characterised TFBSs. 
It is calculated as  
𝑇𝑇𝑇𝑇𝑃𝑃 =  𝑇𝑇𝑇𝑇(𝑇𝑇𝑇𝑇 + 𝐹𝐹𝑇𝑇)  (2. 2) 
 
Where 𝑇𝑇𝑇𝑇 is the number of true positives and 𝐹𝐹𝑇𝑇 is the number of false 
positives. 
The geometric accuracy (ACCg) describes the trade-off between the 
sensitivity and positive predictive value and is calculated as 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 =  √𝑆𝑆𝑆𝑆 × 𝑇𝑇𝑇𝑇𝑃𝑃   (2. 3) 
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In order to create the randomized gene sequences for the negative control, 
all the DNA sequences were scrambled using the shuffleseq program from 
the EMBOSS suite (Rice et al., 2000).  
In the case of the TFBSs predicted using scrambled sequences, there are no 
actual positives and therefore no true positives or false negatives. Any 
predictions are therefore classified as false positives. Performance was thus 
assessed for the scrambled sequences by calculating false positive rate 
which is described here as the ‘false positive rate on scrambled sequences’ 
(FPRs).  The above steps are summarised in Figure 2.4. 
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Figure 2.4: Flowchart summarising methods to evaluate performance of 
pattern matching tools.  
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The FPRs is calculated as 
𝐹𝐹𝑇𝑇𝐹𝐹𝐹𝐹 = 𝐹𝐹𝑁𝑁
𝐴𝐴𝐹𝐹
   (2. 4) 
                                                                                                              
Where 𝐹𝐹𝑁𝑁 is the number of predicted sites and 𝐴𝐴𝐹𝐹 is the number of actual 
negatives.  
As discussed in section 2.2.1, obtaining the number of actual negatives (AN) 
(and specifically the number of true negatives) is a hard problem. AN is 
normally calculated as 
 𝐴𝐴𝐹𝐹 =  𝐹𝐹𝑇𝑇 +  𝑇𝑇𝐹𝐹  (2. 5)  
 
Where 𝐹𝐹𝑇𝑇  is the number of false positives and 𝑇𝑇𝐹𝐹  is the number of true 
negatives 
 
                                                                                                                          
In calculating FPRs, the AN was defined as 
𝐴𝐴𝐹𝐹 =  𝐿𝐿
𝑙𝑙𝑡𝑡
     (2. 6) 
                                                                                                                                     
Where 𝐿𝐿 is the length of the DNA sequence and 𝑙𝑙𝑡𝑡 is the length of the PWM 
in question. 
The FPRs was averaged across the transcription factors and genes 
analysed.  
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2.3 Results and Discussion 
Table 2.4 shows that FIMO (Grant et al., 2011) and MCAST (Bailey and 
Noble, 2003) are the best performing pattern matching tools that predict 
individual TFBSs and clusters of TFBSs respectively. In general, the pattern 
matching tools predicting individual TFBSs perform better than those 
predicting clusters of TFBSs. Because of the more stringent requirements for 
a true positive in predicting clusters of TFBSs (i.e. every predicted site within 
the cluster must have a minimum 70% overlap with a true site), it might be 
expected that the sensitivity for pattern matching tools that predict clusters of 
TFBSs would be lowered, while the specificity would be improved. Indeed, 
the sensitivity of the pattern matching tools that predict clusters of TFBSs is 
somewhat lower than the pattern matching tools that predict individual 
TFBSs. Since the true negative count is not available, the specificity cannot 
be calculated, but surprisingly the FPRs for the pattern matching tools that 
predict clusters of TFBSs is larger than that for the pattern matching tools 
that predict individual TFBSs suggesting that the pattern matching tools that 
predict clusters of TFBSs have lower specificity. 
While the pattern matching tools that predict individual TFBSs outperform 
those that predict clusters of TFBSs, the choice of the type of pattern 
matching tool depends on the context in which it is to be used. 
Consequently, if prior knowledge is available about the DNA sequence being 
scanned (i.e. a ChIP-Seq region) then using a pattern matching tool that 
predicts individual TFBSs is probably a sensible strategy. When analysing a 
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stretch of DNA with no prior knowledge about the presence of a gene, it 
would be better to use a prediction tool that identifies clusters of TFBSs 
since the chance of a random match is much reduced. 
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 Sn PPV  ACCg FPRs 
Individual     
FIMO 0.815 0.735 0.774 0.015 
Patser 0.722 0.653 0.687 0.016 
PoSSuMsearch 0.708 0.635 0.670 0.020 
Clover 0.673 0.584 0.627 0.023 
matrix-scan 0.647 0.579 0.612 0.028 
Cluster     
MCAST 0.774 0.683 0.727 0.033 
BayCis 0.598 0.497 0.545 0.040 
Cister 0.635 0.565 0.599 0.040 
Cluster-Buster 0.657 0.581 0.617 0.039 
Comet 0.682 0.589 0.634 0.038 
 
Table 2.4: Performance of the selected pattern matching tools using PWMs from 
JASPAR.2010.  Average sensitivities (Sn), Positive Predictive Value (PPV) and 
geometric accuracy (ACCg) are reported together with the false positive rate using 
scrambled sequences (FPRs). Performance evaluation was performed across the 
15 transcription factors that overlap between PAZAR and JASPAR. 
 
 
 
. 
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2.4 Conclusions 
As a comprehensive set of experimentally-characterized transcription factor 
binding sites is not available, having good reliable prediction methods is very 
important. While the need for these as an adjunct to gene prediction in the 
human genome has diminished owing to the wide scale experimental 
characterisation of transcription factor binding via high-throughput ChIP 
experiments, it is now much more important in order to have a full 
understanding of the regulation of gene expression, and to be able to 
consider the potential phenotypic effects of mutations occurring in a TFBS.  
However, these high-throughput ChIP experiments do not identify the 
precise TFBS; therefore, in order to make full use of the experimental maps 
of transcription factor binding, the precise TFBS must still be identified within 
a much wider window of bases. This needs to be done by computational 
prediction.  
Evaluating the performance of the pattern matching tools has the potential to 
improve the computational prediction of TFBSs, and hence, aid the analysis 
and interpretation of data from large scale sequencing projects. 
In this chapter,  a set of transcription factor binding site prediction tools that 
could be downloaded and installed locally have been evaluated, identifying 
FIMO and MCAST as the best-performing tools for identifying individual 
TFBSs and clusters of TFBSs respectively.  
 
 
87 
 
 
3 An Independent Assessment of 
Motif Discovery Tools 
 
 
 
Parts of the work presented in this chapter have been published in BMC 
Bioinformatics (Jayaram, N., Usvyat, D. and Martin, A.C.R. “Evaluating tools 
for transcription factor binding site prediction”, BMC Bioinformatics, in press). 
DOI: 10.1186/s12859-016-1298-9 
 
In the previous chapter, the performance of a set of pattern matching tools in 
TFBS prediction was evaluated. The tool FIMO was found to be the best 
performing. However, in addition to having a pattern matching tool with as 
high a performance as possible, the computational prediction of TFBSs 
requires a set of high quality PWMs.   
The aims of this chapter are firstly to conduct an independent assessment, 
using the ENCODE ChIP-Seq data, of the locally-installable motif discovery 
tools that are able to handle large volumes of data; Secondly, to generate a 
set of PWMs using these data with the best-performing motif discovery tool; 
Finally, to check that the selection of the best pattern matching tool is not 
unduly influenced by the choice of PWMs. 
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3.1 Introduction 
 
3.1.1 De Novo Motif Discovery 
PWM models are derived by de novo motif discovery from a set of TFBSs 
that have been experimentally determined to bind a particular transcription 
factor. This is done by using one of several de novo motif discovery 
programs which identify a common over-represented signature, or motif, and 
derive a PWM for the transcription factor (Narlikar and Ovcharenko, 2009).  
Motif discovery tools exist in both online and locally-installable forms. The 
online forms of the motif discovery tools are only capable of deriving PWMs 
for a very limited number of DNA sequences. Therefore, in order to perform 
any bulk analysis, the locally-installable forms of the motif discovery tools 
need to be used. 
A plethora of classical de novo motif discovery tools (i.e. deriving PWMs 
from a set of TFBSs collated from SELEX or individual promoter assays) 
have been developed. The classical de novo motif discovery tools that have 
a locally-installable version are: AlignAce (Hughes et al., 2000), Consensus 
(Hertz and Stormo, 1999), GLAM (Frith et al., 2004b), The Improbizer (Ao et 
al., 2004) , MEME (Bailey and Elkan, 1994), MotifSampler (Thijs et al., 2001) 
and SesiMCMC (Favorov et al., 2005). 
The large volumes of data generated from the high-throughput techniques 
ChIP-chip and ChIP-Seq have presented challenges to de novo motif 
discovery. For example, a ChIP-Seq experiment can generate over 10,000 
sequences in a single run. However, the conventional de novo motif 
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discovery programs were developed when only a small number of protein-
DNA binding events could be characterised, and as such, are not equipped 
to handle large volumes of data.  
Hence a common practice has been to use these tools on a subset of the 
sequences (Jothi et al., 2008; Valouev et al., 2008; Hu et al., 2010). 
However, Hu et al. (2010) have suggested that this practice will lead to 
inaccurate PWMs. Therefore, the tools ChIPMunk (Kulakovskiy et al., 2010), 
HOMER (Heinz et al., 2010), rGADEM (Mercier et al., 2011) and MEME-
ChIP (Ma et al., 2014; Machanick and Bailey, 2011) have recently been 
developed that are able to handle the large volumes of data generated from 
these high-throughput technologies. All of these tools have a locally-
installable version available. Table 3.1 describes these motif discovery tools 
and provides the URLs for downloading the pattern matching tools together 
with the relevant citations. 
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Tool URL And Citation DESCRIPTION 
ChIPMunk http://autosome.ru/ChIPMunk/ 
(Kulakovskiy et al., 2010) 
Derives PWM from the motif with the 
highest Kullback-Liebler divergence  
HOMER http://homer.salk.edu/homer/ 
(Heinz et al., 2010) 
Derives PWM from the most enriched 
motif  
rGADEM https://www.bioconductor.org/ 
(Mercier et al., 2011) 
Derives PWM from a population of 
spaced dyads formed from 
overrepresented motif 
MEME-ChIP http://meme-suite.org/ 
(Machanick and Bailey, 2011) 
Derives PWM from the most 
statistically significant motif 
 
Table 3.1: Description of the motif discovery tools that are capable of handling large 
volumes of data, URLs for downloading the tools and the relevant citations.   
 
 
 
3.1.2 Details of the motif discovery tools that are able to 
handle large volumes of data 
3.1.2.1 ChIPMunk 
ChIPMunk first searches for the motif with the highest Kullback-Leibler 
divergence. It then constructs a PWM from this motif. ChIPMunk then 
iteratively optimizes this PWM by searching for the hits for this PWM in each 
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sequence with the maximum PWM score, and rebuilds the PWM from these 
new motif occurrences (Kulakovskiy et al., 2010). 
3.1.2.2 HOMER 
HOMER first conducts a global search for the most enriched motif. Motif 
enrichment is calculated using the cumulative hypergeometric distribution. It 
then constructs a position specific probability matrix for the motif with the 
highest enrichment. HOMER then converts the position specific probability 
matrix into a PWM and uses a sensitive local alignment algorithm to optimize 
the PWM (Heinz et al., 2010).  
3.1.2.3 rGADEM 
rGADEM first identifies the overrepresented motif in the input sequence 
data.  This overrepresented motif is then used to construct spaced dyads 
(two sets of motif subsequences separated by a number of unspecified 
bases). A genetic algorithm is then used guide the formation of a population 
of spaced dyads which is then converted to a PWM. This PWM is then 
optimized by an expectation-maximization algorithm (Mercier et al., 2011).  
3.1.2.4    MEME-ChIP 
MEME-ChIP first conducts an exhaustive search for the most statistically 
significant motif. Statistical significance is assessed using the Fisher’s exact 
test. A PWM is then constructed from this motif (Machanick and Bailey, 
2011).  
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3.1.3 Impact of High-Throughput Technologies on Motif 
Discovery 
It has been suggested that PWMs derived from data from the high-
throughput techniques ChIP-chip and ChIP-Seq methods, will be more 
accurate than PWMs derived from data from techniques such as SELEX, or 
compilations of individual promoter assays that detect limited transcription 
factor binding site numbers. Furthermore, the ChIP-Seq technique has been 
found to produce PWMs with greater accuracy than ChIP-chip owing to the 
superior resolution provided by the ChIP-Seq technique (Hu et al., 2010; 
Portales-Casamar et al., 2010). 
3.2 Methods 
 
All software was locally installed. 
 
3.2.1 Overlap between Resources 
There are currently a total of 90 transcription factors that are represented in 
the ENCODE ChIP-Seq data. ChIP-Seq datasets for 29 transcription factors 
have access restrictions. Only the transcription factors that had ChIP-Seq 
datasets with no access restrictions were selected.  
The 61 transcription factors without access restrictions are: AP-2A, AP-2Y, 
ATF3, BHLHE40, BRCA1, BRF2, CHD2, C-FOS, C-JUN, C-MYC, CEBPB, 
CTCF, E2F1, E2F4, E2F6, EBF1, ELK4, ERRA, GATA1, GATA2, GATA3, 
GRP20, GTF2B, HA-E2F1, HNF4A, HSF1, IRF1, IRF3, JUND, KAP1, MAFF, 
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MAFK, MAX, NF-E2, NF-YA, NF-YB, NFKB, NRF1, POL2, PRDM1, RFX5, 
RPC155, SETDB1, SPT20, SREBP1, SREBP2, STAT1, STAT2, STAT3, 
TAL1, TBP, TCF7L2, TFIIIC-110, TR4, USF2, YY1, ZNF143, ZNF217, 
ZNF263, ZNF274 and  ZZZ3. However, in order to perform an independent 
assessment of the different motif discovery tools and to check that the 
selection of the best pattern matching tool is not unduly influenced by the 
choice of PWMs, the transcription factors will need to have experimentally 
characterised TFBSs in PAZAR.    
Out of the selected 61 transcription factors, there are only 13 human 
transcription factors which are represented in the ENCODE ChIP-Seq data 
and have experimentally characterised TFBSs in PAZAR (Portales-Casamar 
et al., 2009) as shown in Figure 3.1. These are BRCA1, E2F1, ELK4, 
GATA2, GATA3, IRF1, MAX, NFKB, STAT1, YY1, CTCF, NF-YA and TAL1. 
Hence, unless otherwise specified, the evaluations discussed in this chapter 
could only be performed for these 13 transcription factors. 
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Figure 3.1: Overlap of transcription factor data.  
The Venn diagram shows overlaps between experimentally characterised TFBSs in 
PAZAR, and those transcription factors represented in the ENCODE ChIP-Seq 
data. 
 
3.2.2 Deriving PWMs 
The methods used for deriving de novo PWMs are summarized in            
Figure 3.2.  
For each transcription factor represented in the ENCODE project, two sets of 
ChIP-Seq samples together with a ChIP-Seq control sample are available for 
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each transcription factor. ChIP-Seq control samples are obtained from a 
mock experiment without the specific antibody (Bardet et al., 2012).    
All of the ChIP-Seq datasets for the selected human transcription factors 
were downloaded from the ENCODE project 
(http://hgdownload.cse.ucsc.edu/goldenPath/) in FASTQ format. It is 
important that the short reads arising from ChIP-Seq are aligned properly to 
the reference genome, otherwise false positives and false negatives would 
arise from the reads being mapped to the wrong location. In order to avoid 
this, the quality of the reads was checked using FastQC (http: 
//www.bioinformatics. babraham.ac.uk/projects/fastqc/). Any adaptors and 
low quality reads were then removed using the FASTX-Toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit/). This was done for all of the ChIP-
Seq datasets for the selected human transcription factors. 
The reads were then mapped to the human genome version hg19 using 
Bowtie (Langmead et al., 2009). This was done for all of the ChIP-Seq 
datasets for the selected human transcription factors. 
Bowtie was chosen because it is the recommended aligner for ChIP-Seq 
data (Bardet et al., 2012). The –best parameter was used so that the best 
alignment for a particular read would be reported. This however tends to 
reduce the speed. The –m parameter was set to 1 to ensure that only reads 
that aligned to one part of the genome were aligned. This is a practice that is 
recommended by Bardet et al. (2012). The –n parameter controls the 
allowed number of mismatches between the read and the genome and 
ranges between 0 and 2. Upon investigation of different values from 0 to 2 
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for –n, a value of 1 was found to give the highest percentage of reads that 
aligned to the genome without ambiguity and was used for all experiments. 
The hg19 version of the human genome, the latest available release at the 
time of doing this work was downloaded from 
ftp://ftp.ccb.jhu.edu/pub/data/bowtie_indexes/hg19.ebwt.zip. The resulting 
Sequence Alignment/Map format (SAM) files were converted to binary 
format (BAM) files, and indexed using SAMtools (Li et al., 2009b). The BAM 
format is the binary version of the SAM format. This step reduces the file 
size, and allows rapid access which is essential given the large size of the 
data (several gigabytes). These BAM files were then converted to BED 
format using the bamtobed program in the BEDTools suite (Quinlan and 
Hall, 2010). These steps were done for all of the ChIP-Seq datasets for the 
selected human transcription factors. 
After the reads were aligned to the reference genome, peak calling was 
performed by identifying statistically significant binding regions that are 
enriched in the ChIP-Seq sample compared with the control sample (Park, 
2009). The use of the control sample in the peak calling step helps to control 
biases and artefacts that occur in the experimental protocol (Park, 2009; 
Bardet et al., 2012) as recommended by Bardet et al. (2012).  Peaks were 
called using MACS (Zhang et al., 2008) for both ChIP-Seq samples for each 
transcription factor in the set of selected transcription factors. MACS was 
chosen as it is the recommended peak caller for calling peaks that are to be 
used in de novo motif discovery (Wilbanks and Facciotti, 2010). Default 
parameters were used as this is the practice recommended by Wilbanks and 
Facciotti (2010) and Bardet et al. (2012). MACS requires the input to be in 
97 
 
BED format hence the reason for converting the BAM files to BED format. 
Common peaks between ChIP-Seq samples for a particular transcription 
factor were selected for further analysis, using the Bioconductor package 
ChIPpeakAnno (Zhu et al., 2010; Gentleman et al., 2004). This is a practice 
that has been recommended by Bailey et al. (2013). A set of peak regions, 
centred on the summits of the peaks (±100 bp), were obtained, in order to 
prevent bias towards longer peak regions (Bardet et al., 2012). These peak 
regions were then converted to FASTA format using the Bioconductor 
package ChIPpeakAnno (Zhu et al., 2010; Gentleman et al., 2004). This is 
because the motif discovery tools require DNA sequences in FASTA format 
as input.   
For evaluation purposes, de novo motif discovery was carried out on the 
peak regions derived from the ENCODE ChIP-Seq data using MEME-ChIP 
(Ma et al., 2014; Machanick and Bailey, 2011), HOMER (Heinz et al., 2010), 
ChIPMunk (Kulakovskiy et al., 2010) and rGADEM (Mercier et al., 2011) for 
the 13 transcription factors that overlap between PAZAR and the ENCODE 
ChIP-Seq data. Since these programs are able to deal with large datasets, 
all peak regions were used.  
 
3.2.3 Finding optimum parameters for the motif discovery 
tools 
 
It is key that the PWM generated for a particular transcription factor matches 
the experimentally validated binding pattern in the literature. The tools have 
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parameters that can be adjusted for motif discovery, and all possible 
combinations of these were explored, using a step size of 10%, in order to 
generate PWMs that resembled the experimentally validated binding pattern 
in the literature. It was found that for MEME-ChIP, HOMER and ChIPMunk 
the default values,for the parameters produced PWMs that resembled the 
experimentally validated binding patterns (i.e. the corresponding sequence 
logo shows a pattern that is close to the experimentally validated binding 
pattern). Any change from the default values produced PWMs that were 
drastically different from these experimentally validated binding patterns (i.e. 
the corresponding sequence logo shows a pattern that is very different from 
the experimentally validated binding pattern). In the case of rGADEM 
however, the e-value parameter had to be set to a value of 0.5, with the 
remainder of the parameters set at their default values, to generate PWMs 
that resembled experimentally validated binding patterns. Again, deviation 
from these values including use of the default e-value of 0.0, resulted in 
PWMs that were drastically different from the experimentally validated 
binding patterns. During the exploration of parameters, it was found that the 
first PWM generated, always best resembled the experimentally validated 
binding pattern, and consequently the motif discovery tools were set to 
generate just one PWM for a particular transcription factor. An example of a 
sequence logo (for the GATA2 transcription factor) that has a binding pattern 
that resembles the experimentally validated binding pattern is shown in 
Figure 3.3. An example of a sequence logo (for the GATA2 transcription 
factor) that has a binding pattern that is drastically different from the 
experimentally validated binding pattern is shown in Figure 3.4.   
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Figure 3.2:  Flowchart summarising methods used to derive PWMs from the 
ENCODE ChIP-Seq data. 
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Figure 3.3: Sequence logo for the GATA2 transcription factor showing a binding 
pattern that resembles the experimentally validated binding pattern (A/TGATA/A/G). 
 
 
 
Figure 3.4: Sequence logo for the GATA2 transcription factor showing a binding 
pattern that is drastically different from the experimentally validated binding pattern 
(A/TGATA/A/G). 
 
3.2.4 Evaluation of Motif Discovery Methods 
Logically, it makes sense, to evaluate motif discovery methods first, and 
then,to evaluate the tools available for matching the derived PWMs to DNA 
sequences. However, the evaluation of the performance of motif discovery 
methods requires a pattern matching tool to test the performance of the 
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resulting PWMs. Therefore, a pattern matching tool must be selected for this 
purpose. In the previous chapter, the performance of a number of pattern 
matching tools in TFBS prediction was evaluated using PWMs from the 2010 
release of JASPAR.  The best performing tool (FIMO) was then used in this 
chapter for evaluating the motif discovery methods. 
The FIMO pattern matching tool requires the input PWMs in MEME format. 
The motif discovery tool MEME-ChIP generates PWMs in this format, while 
the rGADEM, ChIPMunk and HOMER motif discovery tools all produce 
PWMs in tab format. There is no single program capable of converting 
PWMs from tab to MEME format. Therefore, the PWMs that were derived 
using rGADEM, ChIPMunk and HOMER were first converted from tab to 
JASPAR format using the convert-matrix program from the RSAT suite 
(Thomas-Chollier et al., 2011). These were then converted from JASPAR to 
MEME format using the jaspar2meme program , from MEME-SUITE (Bailey 
et al., 2015).   
Performance was evaluated on the PWMs that resembled well established 
motifs by using the FIMO motif scanning tool using the protocol outlined in 
section 2.2.1 with the exception that since the evaluation was performed 
over the 13 transcription factors that overlapped between PAZAR and 
ENCODE ChIP-Seq the number of genes used in the evaluation was 167.  
The PWMs obtained using the different methods were compared with each 
other in terms of their similarity. This was done by the calculation of 
normalised Euclidean distances between equivalent PWMs using the 
TFBSTools package in Bioconductor 
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(http://www.bioconductor.org/packages/release/bioc/html/TFBSTools.html). 
The normalised Euclidean distance was chosen as it has been found to be 
the most effective method for comparing PWM similarity (Gupta et al., 2007). 
Reverse complement matrices were also checked, and the minimum 
distances recorded. Results for each matrix set comparison were averaged 
across the transcription factors used. The normalised Euclidean distance 
ranges from 0 to 1 where 0 denotes complete identity and 1 denotes 
complete dissimilarity. The normalised Euclidean distance is calculated as 
follows: 
𝐷𝐷(𝑎𝑎, 𝑏𝑏) =  12𝑙𝑙  .�� � �𝑁𝑁𝑖𝑖,𝑏𝑏    −1 𝑁𝑁𝑖𝑖,𝑏𝑏 2 �2  
𝑏𝑏∈{𝐴𝐴,𝐶𝐶,𝐺𝐺,𝑇𝑇}
𝑙𝑙
𝑖𝑖=1
      (3.1) 
Where 𝑙𝑙 is the length of the PWM,  𝑁𝑁𝑖𝑖,𝑏𝑏    1 is the value in column 𝑖𝑖    with DNA 
base 𝑏𝑏 for PWM 1 and 𝑁𝑁𝑖𝑖,𝑏𝑏 2 is the value in column 𝑖𝑖    with DNA base 𝑏𝑏 for 
PWM 2. 
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3.3 Results and Discussion 
 
3.3.1 Evaluating the Performance of Motif Discovery Tools 
Table 3.2 shows that rGADEM has the best performance and MEME-ChIP 
the worst on all four performance measures. 
Table 3.3 shows that by comparing the PWMs generated in this work using 
different motif discovery tools, that while all PWMs resemble experimentally 
validated binding patterns, there are significant differences in the PWMs 
generated by different motif discovery tools.  
Table 3.3 also shows that the largest difference is between the PWMs 
derived using the best performing method (rGADEM) and PWMs from the 
worst performing method (MEME-ChIP).   
Figure 3.5 shows the similarity between the PWMs generated by the 
different motif discovery tools in the form of a tree. This was created by using 
Table 3.3 as vectors for clustering using Ward's minimum variance technique 
and visualised using the DRAWGRAM utility from the Phylip package 
(http://evolution.genetics.washington.edu/phylip.html). 
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TOOL Sn PPV  ACCg FPRs 
ChIPMunk 0.886 0.786 0.835 0.009 
MEME-ChIP 0.865 0.771 0.817 0.012 
rGADEM 0.932 0.840 0.885 0.002 
HOMER 0.901 0.794 0.846 0.007 
 
Table 3.2: Performance of the different motif discovery tools using FIMO. 
Average sensitivities (Sn), Positive Predictive Value (PPV) and geometric accuracy 
(ACCg) and false positive rate on scrambled sequences (FPRs) are reported. Note 
that PWMs were generated only for the 13 transcription factors that overlap 
between the ENCODE ChIP-Seq data and PAZAR data. 
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Table 3.3: Normalised Euclidean distances between PWMs derived using the 
different motif discovery tools. Note that comparisons between the matrices 
generated in this work were performed over the 13 PWMs which were used for 
performance evaluation (i.e. those that correspond to transcription factors that 
overlap between ENCODE-ChIP-Seq data and PAZAR). 
 
 rGADEM HOMER ChIPMunk MEME-ChIP 
rGADEM 0 ─ ─ ─ 
HOMER 0.161 0 ─ ─ 
ChIPMunk 0.264 0.120 0 ─ 
MEME-ChIP 0.372 0.202 0.153 0 
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Figure 3.5: Tree showing the similarity between the PWMs generated by the 
different motif discovery tools.  
3.3.2 Derivation of a New Set of PWMs 
 
Having shown that the rGADEM motif discovery method clearly out-performs 
the other methods, motif discovery was then performed on a further set of 48 
transcription factors, using rGADEM on the peak regions derived from the 
ENCODE ChIP-Seq data. It was decided to store the PWMs in MEME format 
as this is the format required for FIMO which is the best performing pattern 
matching tool. There is no single program capable of converting PWMs from 
tab to MEME format. Therefore the resulting PWMs were converted from the 
tab to JASPAR format using the convert-matrix program from the RSAT suite 
(Thomas-Chollier et al., 2011) and then from JASPAR to MEME format using 
the jaspar2meme program , from  MEME-SUITE (Bailey et al., 2015).     
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3.3.3 The hCRM Resource  
 
The 61 PWMs derived using rGADEM were then made publically available 
via the web. This new resource is referred to hereafter as the ‘human ChIP-
Seq rGADEM matrices’ (hCRM) and they may be downloaded from 
http://www.bioinf.org.uk/tfbs/.  The hCRM PWMs can be obtained individually 
or via bulk download as a ZIP file or gzipped tar file. This web site also 
allows the matrices to be browsed and viewed as ‘sequence logos’, and 
downloaded individually. The two ways the website can be displayed are 
summarised in Figure 3.6 and Figure 3.7. 
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Figure 3.6:  Screenshot from the website showing an individual hCRM PWM, its 
sequence logo and the link to download the PWM in MEME format. 
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Figure 3.7:  Screenshot from the website showing the hCRM PWMs and the link to 
bulk download them in MEME format. 
 
3.3.4 Comparison of the hCRM and JASPAR.2010 PWMs 
Table 3.4 shows the sequence logos for the PWMs that are present in both 
JASPAR.2010 and hCRM together with the normalized Euclidean distance. 
It can be observed from Table 3.4 that while both the hCRM and 
JASPAR.2010 PWMs for the transcription factors ELK4, GATA2, GATA3, 
IRF1, MAX, CTCF, NF-YA and YY1 resemble the experimentally validated 
binding pattern, there are significant differences between the hCRM and 
JASPAR.2010 PWMs and that these differences are higher than the 
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differences observed in Table 3.2 from the comparison of PWMs derived 
using different motif discovery tools.   
It can also be observed from Table 3.4 that there are also significant 
differences between the hCRM and JASPAR.2010 PWMs for the 
transcription factors BRCA1, E2F1, NFKB and STAT1. These differences 
are higher than the differences between the hCRM and JASPAR.2010 PWM 
for the transcription factors ELK4, GATA2, GATA3, IRF1, MAX, CTCF, NF-
YA and YY1 and even higher than the differences observed in Table 3.2 from 
the comparison of PWMs derived using different motif discovery tools. 
However for the transcription factors BRCA1, E2F1, NFKB and STAT1 only 
the hCRM PWMs resemble the experimentally validated binding pattern. 
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Table 3.4: Sequence logos for the PWMs present in both JASPAR.2010 and hCRM 
together with their normalized Euclidean distances. 
 hCRM Logo JASPAR.2010  
Logo 
Euclidean 
Distance 
BRCA1 
  
0.709 
E2F1 
  
0.591 
ELK4 
 
 
0.462 
GATA2 
  
0.477 
GATA3 
  
0.471 
IRF1 
 
 
0.430 
MAX 
 
 
0.468 
NFKB 
  
0.679 
STAT1 
  
0.590 
CTCF 
  
0.439 
NF-YA 
  
0.446 
YY1 
  
0.403 
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3.3.5 Re-Evaluation of Pattern Matching Tools 
 
Having shown that rGADEM generates better PWMs than other motif-
discovery methods, the objective was then to reassess the performance of 
all the pattern matching tools investigated in the previous chapter. 
Performance, however, could only be assessed for the 13 transcription 
factors that overlap PAZAR and hCRM.  The hCRM PWMs are in MEME 
format which is the required format for the FIMO and MCAST pattern 
matching tools, and an accepted format for the matrix-scan pattern matching 
tool. The convert-matrix program from the RSAT suite was used to convert 
the PWMs into the Cluster-Buster format required for the pattern matching 
tools Cister, Cluster-Buster, and Comet and into the tab format required for 
the Patser and BayCis pattern matching tools. To convert the PWMs into the 
PoSSuM-PSSM format required for the PoSSuMsearch pattern matching 
tool, the convert-matrix program from the RSAT suite (Thomas-Chollier et 
al., 2011) was used to convert the PWMs from MEME to TRANSFAC format 
and the transfac2gen program (included with the PoSSuMsearch download) 
was then used to convert the PWMs from TRANSFAC to the PoSSuM-
PSSM format. The performance of the pattern matching tools was then 
reassessed by using the protocol described in section 2.2.1 with the 
exception that, since the evaluation was performed over the 13 transcription 
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factors that overlapped between PAZAR and hCRM, the number of genes 
used in the evaluation was 167.  
In the previous chapter, FIMO was identified as the best pattern matching 
tool for predicting individual TFBSs and MCAST was identified as the best 
pattern matching tool for predicting clusters of TFBSs using the 
JASPAR.2010 PWMs. Table 3.5 shows that these two tools still perform best 
using the hCRM PWMs derived here. Indeed the overall ranking of all the 
tools remains the same: 
MCAST > Comet > Cluster-Buster > Cister > BayCis for cluster predictions 
and 
FIMO > Patser > PoSSuMsearch > Clover > matrix-scan for individual 
predictions. 
While evaluated on slightly different datasets, comparing the results in   
Table 2.4 (where tool evaluation was performed using JASPAR.2010 PWMs 
over 15 transcription factors that overlap between PAZAR and JASPAR) with 
the results in Table 3.5 (where tool evaluation was performed using hCRM 
PWMs over 13 transcription factors that overlap between PAZAR and 
hCRM) clearly shows that the hCRM PWMs (derived from ChIP-Seq data) 
outperform the JASPAR.2010 PWMs (derived from SELEX or individual 
promoter assays) regardless of the choice of PWM scanning tool.  
While it is possible that there is some inter-relationship between the choice 
of motif discovery method and the pattern matching tool used to search 
those motifs against a DNA sequence, this seems unlikely to be significant. 
The ranking of tool performance was the same when used with the 
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JASPAR.2010 PWMs and the hCRM PWMs. Similarly, using FIMO, PWMs 
generated using rGADEM were shown to outperform those generated using 
MEME-ChIP. 
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 Sn PPV ACCg FPRs 
Individual     
FIMO 0.932 0.840 0.885 0.002 
Patser 0.887 0.774 0.829 0.009 
PoSSuMsearch 0.874 0.758 0.814 0.012 
Clover 0.850 0.736 0.791 0.015 
matrix-scan 0.830 0.718 0.772 0.018 
Cluster     
MCAST 0.907 0.779 0.840 0.014 
BayCis 0.792 0.688 0.738 0.024 
Cister 0.829 0.723 0.774 0.022 
Cluster-Buster 0.849 0.739 0.792 0.019 
Comet 0.870 0.759 0.813 0.015 
 
Table 3.5: Performance of the selected pattern matching tools using the hCRM 
PWMs derived in this work.  Average sensitivities (Sn), Positive Predictive Value 
(PPV) and accuracy (ACCg) are reported together with the false positive rate using 
scrambled sequences (FPRs). Performance was evaluated across the 13 
transcription factors that overlap the hCRM matrices and PAZAR.  
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3.4 Conclusions 
 
In conclusion, it has been shown that PWMs derived from the ENCODE-
ChIP-Seq data using rGADEM outperform those derived using other motif 
discovery methods. Consequently, the resulting hCRM dataset should be 
regarded as an enhanced addendum to resources such as JASPAR, 
HOCOMOCO, HOMER and CIS-BP. Clearly, as more ChIP-Seq data 
become available, additional PWMs will be able to be generated. 
The hCRM matrices have been made publicly available for free download 
from http://www. bioinf.org.uk/tfbs/.  
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4 Prioritization of Somatic Driver SNVs 
in TFBSs 
 
The aims of this chapter are: firstly, to exploit the analyses in the previous 
two chapters in order to perform a more comprehensive prediction of precise 
TFBSs, secondly, to perform an analysis of the conservation of the positions 
of somatic driver and passenger SNVs that occur in TFBSs, and finally to 
exploit this analysis to help prioritize candidate somatic driver SNVs in 
TFBSs for experimental validation. 
 
4.1 Introduction  
4.1.1 Somatic SNVs in Cancer 
Cancer is a leading cause of death worldwide. This is expected to increase 
further due to the ageing population with cancer being expected to surpass 
heart disease as the main killer (Wishart, 2015; Gutschner and Diederichs, 
2012). Cancer is characterised as a group of abnormal cells that grow 
outside of the normal cell growth boundaries. This behaviour is characterised 
by six hallmarks which together form the fundamental principles of malignant 
tumour formation (Gutschner and Diederichs, 2012):  (i) evasion of apoptosis 
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(therefore resisting cell death), (ii) self-sufficiency in growth signals, (iii) 
insensitivity to anti-growth signals, (iv) sustained angiogenesis (which 
enables a consistent supply of nutrients and oxygen and the removal of 
carbon dioxide and waste products generated from metabolism), (v) limitless 
replicative potential and (vi) tissue invasion and metastasis (Hanahan and 
Weinberg, 2000). This is summarised in Figure 4.1. The acquisition of these 
hallmarks is dependent on the accumulation of mutations. However, the 
rates of spontaneous mutation are very low due the ability of the genome 
maintenance systems to detect and repair mutations. Therefore, in order to 
acquire the above six cancer hallmarks, cancer cells need to increase the 
rate of mutation. This is done by mutating the various genes involved in the 
genome maintenance system e.g. TP53 (Hanahan and Weinberg, 2011). 
 
Figure 4.1: The six hallmarks of cancer (Hanahan and Weinberg, 2011). 
 
The majority of these mutations tend to be somatic SNVs (Meyerson et al., 
2010). While many somatic SNVs occur in the coding regions, the majority 
occur in the non-coding regions (Pon and Marra, 2015).  In relation to 
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cancer, there are two types of somatic SNVs: drivers and passengers. Driver 
SNVs are defined as rare SNVs that confer a selective growth advantage to 
the cell. Passenger SNVs are defined as SNVs that do not confer a growth 
advantage to the cell, and are not directly involved in cancer formation 
(Vogelstein et al., 2013). Common SNVs (occurring in >1% of the 
population) are automatically classified as passenger SNVs. Therefore, 
passenger SNVs comprise a mixture of rare and common SNVs (Pon and 
Marra, 2015). Clearly research in cancer genetics is heavily focussed on 
driver rather than passenger SNVs (McFarland et al., 2013). 
There has been a comprehensive characterisation of somatic SNVs across a 
large number of tumour samples. This has been enabled by the recent 
advances in technologies for massively parallel sequencing of DNA that 
allow sequencing of whole exomes and genomes (Watson et al., 2013).  
This in turn has led to large scale projects such as The Cancer Genome 
Atlas (TCGA) (Weinstein et al., 2013), and the International Cancer Genome 
Consortium (ICGC) (Hudson et al., 2010).   
Consequently, there has been a huge rise in the number of somatic driver 
SNVs identified, and these are deposited in the databases COSMIC (Forbes 
et al., 2015), ICGC (Hudson et al., 2010) and TCGA (Weinstein et al., 2013). 
The data in COSMIC are a superset of ICGC and TCGA making COSMIC  
the largest and most comprehensive resource of somatic cancer SNVs 
(Forbes et al., 2015; Chin et al., 2011).     
The rise of whole genome sequencing of human cancers has opened up the 
opportunity to study the large numbers of somatic SNVs that occur in       
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non-coding regions (Poulos et al., 2015a).  It has been found that over 40% 
of somatic SNVs occur in TFBSs, and somatic SNVs are statistically 
enriched in TFBSs (P < 1 × 10−10, two-sided Fisher’s exact test) (Mathelier et 
al., 2015b; Melton et al., 2015). Somatic SNVs occurring in TFBSs have also 
been found to have the potential to disrupt the binding of transcription 
factors, thereby altering the gene expression of the corresponding gene, and 
therefore aiding the survival and proliferation of cancer cells (Mathelier et al., 
2015c; Melton et al., 2015; Poulos et al., 2015b). It has therefore been 
suggested  that somatic SNVs in TFBSs are a source of unidentified somatic 
driver SNVs (Poulos et al., 2015a), and that the identification of somatic 
driver SNVs in TFBSs will improve diagnosis and enable more personalised 
therapies (Pabinger et al., 2014). 
There is now a clear need to analyse somatic driver and passenger SNVs in 
TFBSs and use the results of these analyses to help prioritize candidate 
somatic driver SNVs in TFBSs for experimental validation due to the sheer 
volume of data being generated. In order to fulfil this need, there has to be a 
focus on the computational prediction of TFBSs. This is important in order to 
identify the somatic SNVs that occur in TFBSs given the limited number of 
experimentally characterised TFBSs. In chapters 2 and 3, independent 
performance evaluations were carried out to identify the best performing 
pattern matching and motif discovery tools which in turn will aid TFBS 
prediction.  
4.2 Methods 
All software was locally installed. 
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4.2.1 Prediction of TFBSs 
The standard practice of predicting the TFBSs within ChIP-Seq regions 
when the resulting predicted TFBSs are to be used for the identification of 
SNVs in TFBSs was adopted (Mathelier et al., 2015c). This ensured that a 
very reliable set of predicted TFBSs was obtained. 
ChIP-Seq peaks were downloaded from the ENCODE project 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeSy
dhTfbs/) in plain text format. This is the standard dataset used for predicting 
TFBSs and identifying SNVs within them (Mathelier et al., 2015c). As 
mentioned in section 3.2.1, 61 of the 90 transcription factors represented in 
the ENCODE project have no access restrictions and had their 
corresponding ChIP-Seq peaks downloaded. These transcription factors are 
AP-2A, AP-2Y, ATF3, BHLHE40, BRCA1, BRF2, CHD2, C-FOS, C-JUN, C-
MYC, CEBPB, CTCF, E2F1, E2F4, E2F6, EBF1, ELK4, ERRA, GATA1, 
GATA2, GATA3, GRP20, GTF2B, HA-E2F1, HNF4A, HSF1, IRF1, IRF3, 
JUND, KAP1, MAFF, MAFK, MAX, NF-E2, NF-YA, NF-YB, NFKB, NRF1, 
POL2, PRDM1, RFX5, RPC155, SETDB1, SPT20, SREBP1, SREBP2, 
STAT1, STAT2, STAT3, TAL1, TBP, TCF7L2, TFIIIC-110, TR4, USF2, YY1, 
ZNF143, ZNF217, ZNF263, ZNF274 and  ZZZ3.  
These ChIP-Seq peaks were then converted to FASTA format using the 
Bioconductor package ChIPpeakAnno (Zhu et al., 2010; Gentleman et al., 
2004) because the FIMO tool (Grant et al., 2011),  requires the input DNA 
sequences to be in FASTA format.  Prediction of TFBSs was carried out on 
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these sequences using FIMO which was identified as the best performing 
pattern matching tool in chapter 2, and the hCRM PWMs derived using 
rGADEM (Mercier et al., 2011), which was identified as the best performing 
motif discovery tool in chapter 3.   
The resulting predicted TFBSs were converted to BED format using 
PyBedTools (Dale et al., 2011).  As mentioned in section 2.2.1, the 
coordinates of the predicted TFBSs from FIMO are relative to their larger 
genomic fragments (i.e. are relative coordinates), while the coordinates of 
the ChIP-Seq peaks obtained from the ENCODE project are genomic 
coordinates i.e. describing their actual location in the genome. Therefore, in 
order to identify SNVs in TFBSs, the  coordinates of the resulting predicted 
TFBSs were converted from relative coordinates to genomic coordinates 
using the convert-feature program from RSAT (Thomas-Chollier et al., 2011) 
with output in BED format. The genomic coordinates of the ChIP-Seq peaks 
obtained from the ENCODE project was provided as the source of genomic 
coordinates to the convert-feature program.  These were converted to BED 
format using Pybedtools (Dale et al., 2011).  As mentioned in section 2.2.1, 
the convert-feature program requires all input files in BED format. The above 
steps are summarised in Figure 4.2. 
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Figure 4.2: Flowchart showing the prediction of TFBSs within ENCODE ChIP-Seq 
peaks.  
 
ENCODE ChIP-Seq data 
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Set of predicted precise TFBSs 
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4.2.2 Obtaining a Set of Somatic Cancer Driver and 
Passenger SNVs That Occur In TFBSs 
Non-coding somatic cancer SNVs were downloaded from COSMIC (Forbes 
et al., 2015) version 73 (the latest version at the time of doing this work) in 
VCF format. This VCF file is sorted by chromosome in ascending order. A 
total of 9 million non-coding somatic SNVs were downloaded. It was decided 
to use only the non-coding somatic SNVs in COSMIC given that questions 
have been raised whether TFBSs in protein coding regions are functional in 
terms of regulation of gene expression (Xing and He, 2015). 
These non-coding somatic SNVs were then mapped to the predicted TFBSs 
and annotated with their minor allele frequency (from the 1000 genomes 
project) and the distance of each of the predicted TFBSs from the 
transcription start site. This was done using the variant_effect_predictor.pl 
program from the Ensembl VEP (McLaren et al., 2010), which utilises the 
Ensembl API . Prior to this, the predicted TFBSs were sorted, compressed 
using bgzip  (Li et al., 2009b), and then indexed using Tabix (Li et al., 2009b) 
which was required to enable the variant_effect_predictor.pl program to map 
the SNVs to the predicted TFBSs. The SNVs that were found to occur in the 
predicted TFBSs were annotated with the keyword FIMO-TFBS, together 
with the name of the corresponding transcription factor using the custom 
annotation capabilities of the Ensembl VEP. Version 81 of both the Ensembl 
VEP and Ensembl API was used, as these were the latest available versions 
at the time of doing this work. The Ensembl VEP was chosen because it has 
a flexible method of filtering results with the capability of the user writing their 
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own filter strings, and it has the ability to incorporate allele frequency 
information (Erzurumluoglu et al., 2015). 
Initially the variant_effect_predictor.pl program was very slow to run          
(~9 hours). In order to improve the run time, several steps were implemented 
as recommended on the Ensembl VEP website. These are described below: 
1. First a cache file was downloaded for the human genome from                                                                              
ftp://ftp.ensembl.org/release81/VEP/homo_sapiens_vep_81.tar.gz 
2. The --cache flag for the variant_effect_predictor.pl program was 
enabled in order to use the cache file. This step reduced the runtime 
by 3 hours. 
3. The –offline flag for the variant_effect_predictor.pl program was then 
enabled in order to prevent the program accessing the Ensembl 
database, as retrieving information from only the cache file on the 
local file system is faster than retrieving information from the Ensembl 
database even if it is locally installed. This step reduced the runtime 
by a further 2 hours.  
4. The convert_cache.pl script from the Ensembl VEP was then used to 
convert the cache file to a Tabix indexed file. This step reduced the 
runtime by a further 3 hours.  
5. The Ensembl-XS package was then used to improve the run time still 
further as this package contains fast re-implementations in C of 
several key subroutines used in the variant_effect_predictor.pl 
program. This step reduced the runtime to 20 mins.  
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Therefore, the run time was greatly reduced from ~ 9 hours to 20 mins by the 
implementation of the above steps. 
The 9 million non-coding somatic SNVs were then filtered to exclude any 
SNVs that were not annotated with the keyword FIMO-TFBS, and therefore, 
not found to occur in TFBSs. The resulting set of 159901 SNVs that were 
found to occur in TFBSs were then filtered further to obtain the sets of 
somatic driver and passenger SNVs that occur in TFBSs. The set of somatic 
driver SNVs in TFBSs were obtained by filtering these SNVs to exclude any 
SNVs that were not annotated by COSMIC as being a known driver SNV. 
 A total of 72329 somatic driver SNVs that occurred in TFBSs were obtained. 
As a set of experimentally characterised passenger SNVs is not available, 
the standard practice of selecting only common SNVs (with a minor allele 
frequency >0.01) was employed to classify these SNVs as passengers (Pon 
and Marra, 2015).  A total of 87572 somatic passenger SNVs that occurred 
in TFBSs was obtained. These steps are summarised in Figure 4.3. The 
filtering was done using the filter_vep.pl program from the Ensembl VEP. 
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Figure 4.3: Flowchart summarising the steps taken to obtain the set of somatic 
driver and passenger SNVs in TFBSs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
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4.2.3 Assessment of the Conservation of Positions of 
Somatic Driver and Passenger SNVs in TFBSs 
A somatic SNV that occurs at a position in the TFBS that is more conserved 
is likely to be much more disruptive to the binding of transcription factors to 
DNA, than a somatic SNV that occurs at a position in the TFBS with low 
conservation (Cline and Karchin, 2011; Gonzalez-Perez et al., 2013). This is 
because, more conserved positions reflect the fact that the transcription 
factor requires a particular nucleotide for binding. There are several 
measures of assessing conservation. However, only the Shannon entropy 
measure is applicable to nucleotide sequences and was hence chosen for 
the assessment of conservation of the positions of the somatic driver and 
passenger SNVs in TFBSs.  This is because the remainder of the measures 
take into account the biochemical properties of amino acids (Gonzalez-Perez 
et al., 2013; Poulos et al., 2015a; Mathelier et al., 2015b; Spivakov et al., 
2012; Cline and Karchin, 2011; Johansson and Toh, 2010; Capra and Singh, 
2007).  
Conservation of the positions of the somatic driver and passenger SNVs in 
TFBSs was assessed by calculating Shannon Entropies for the somatic 
driver and passenger SNVs in TFBSs using the TFBSTools package in 
Bioconductor 
(http://www.bioconductor.org/packages/release/bioc/html/TFBSTools.html). 
Shannon Entropy (H) is calculated as follows  
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𝐻𝐻 =  −�𝑁𝑁𝑖𝑖 𝑙𝑙𝑙𝑙𝐴𝐴𝑏𝑏 𝑁𝑁𝑖𝑖
𝑖𝑖
    (4. 1) 
Where 𝑁𝑁𝑖𝑖 is the probability of the character 𝑖𝑖 and 𝑏𝑏 is the base of the 
logarithm. This is normally 2 (Spivakov et al., 2012). For DNA, the Shannon 
entropy ranges from 0 to 2 where 0 denotes complete conservation and 2 
denotes an equal probability of all four bases when 𝑏𝑏= 2.  
 
4.3 Results and Discussion 
4.3.1 Analysis of the Conservation of the Positions of 
Somatic Driver and Passenger SNVs in TFBSs 
 
A histogram of the Shannon entropies of somatic driver and passenger 
SNVs in TFBSs (calculated as described in section 4.2.3) was plotted using 
the ggplot2 package (Wickham, 2009) in R (Team, 2014). This is shown in 
Figure 4.4.  
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Figure 4.4: Shannon Entropies of somatic driver and passenger SNVs. 
 
Within TFBSs certain positions are more conserved and certain other 
positions have low conservation.  
 Figure 4.4 shows that somatic driver SNVs in TFBSs tend to be at more 
conserved positions within the TFBSs, and therefore, have lower Shannon 
entropies (no somatic driver SNVs have a Shannon entropy of >1.3) while 
somatic passenger SNVs in TFBSs tend to be at positions within the TFBSs 
with low conservation and therefore have higher Shannon entropies (no 
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somatic passenger SNVs have a Shannon entropy of <0.8). This suggests 
that somatic driver SNVs TFBSs and somatic passenger SNVs only occur at 
certain distinct positions within the TFBSs.  
 Figure 4.4 also shows that the Shannon entropies of the somatic driver and 
passenger SNVs are normally distributed. 
 While the separation was very clear, a two sample Welch’s t-test was 
performed in order to assess whether there was a significant difference in 
the conservation of the positions of the somatic cancer driver SNVs in 
TFBSs, and the somatic cancer passenger SNVs in TFBSs. This was done 
using the t.test function in R (Team, 2014) which defaults to the two sample 
Welch t-test. This was chosen because the datasets are normally distributed, 
but with different variances and sample sizes.  
As expected, the two sample Welch t-test showed a very significant 
difference in the conservation of the positions of the somatic cancer driver 
and passenger SNVs in TFBSs with a t statistic of -1002.561 at 154574.5 
degrees of freedom and a  p-value of < 2.2 x 10-16. 
These results show that somatic driver SNVs occur at positions within the 
TFBSs that are more conserved, and somatic passenger SNVs occur at 
positions within the TFBSs that have low conservation.  
Therefore, the results of this analysis could be used to prioritize somatic 
driver SNVs in TFBSs for experimental validation. 
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4.3.2 Using Shannon Entropy to Prioritize Candidate 
Somatic Driver SNVs in TFBSs 
 
The Shannon entropies of the somatic driver and passenger SNVs in TFBSs 
are distinctive. However, Figure 4.4 also shows an overlap between the 
Shannon entropies of somatic driver and passenger SNVs in TFBSs. 
Therefore, in order to use Shannon entropy to prioritize candidate somatic 
driver SNVs in TFBSs effectively, the optimum Shannon entropy threshold 
(i.e. the threshold with the best performance) within this overlap needs to be 
found. An SNV with a Shannon entropy below this threshold can then be 
considered as a candidate somatic driver SNV, while an SNV with a 
Shannon entropy above this threshold can be considered as a candidate 
somatic passenger SNV.  
In order to find this optimum Shannon entropy threshold, the threshold was 
varied along the set of Shannon entropies that were calculated for the 
somatic cancer driver and passenger SNVs occurring in TFBSs. This was 
done in steps of 0.1 from 0 to 2 (the full range of Shannon entropies). A 
driver SNV with a Shannon entropy value at or below the threshold was 
counted as a true positive (TP), while a driver SNV with a Shannon Entropy 
value above the threshold was counted as a false negative (FN). In contrast, 
a passenger SNV with a Shannon entropy value at or below the threshold 
was counted as a false positive (FP), while a passenger SNV with a 
Shannon entropy value above the threshold was counted as a true negative 
(TN). This was done using R (Team, 2014).  For each value of the Shannon 
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entropy threshold, the Matthews Correlation Coefficient (MCC) (Matthews, 
1975) was calculated to assess performance.  
 
𝑀𝑀𝐴𝐴𝐴𝐴 =  𝑇𝑇𝑇𝑇 × 𝑇𝑇𝐹𝐹 − 𝐹𝐹𝑇𝑇 × 𝐹𝐹𝐹𝐹 
�(𝑇𝑇𝑇𝑇 + 𝐹𝐹𝑇𝑇)(𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹)(𝑇𝑇𝐹𝐹 + 𝐹𝐹𝑇𝑇)(𝑇𝑇𝐹𝐹 + 𝐹𝐹𝐹𝐹)    (4. 2) 
 
The MCC was chosen as a performance indicator because, it utilizes 
information on true positives, false positives, true negatives and false 
negatives, and therefore evaluates the performance in a more balanced 
manner than for example sensitivity or specificity (Baldi et al., 2000). A graph 
of MCC against Shannon entropy threshold was then generated using R 
(Team, 2014) as shown in Figure 4.5. 
134 
 
 
Figure 4.5: MCC plotted against Shannon entropy threshold for the full range of 
Shannon entropies (0 to 2). 
 
 Figure 4.5 shows that the optimum Shannon entropy threshold lies between 
1 and 1.1. In order to identify the optimum Shannon entropy threshold more 
precisely, the protocol used to calculate the MCC described in section 4.3.2 
was repeated, but this time between 1 and 1.1 in steps of 0.01. Another 
graph of MCC against Shannon entropy threshold was generated using R 
(Team, 2014) as shown in Figure 4.6. 
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Figure 4.6: MCC plotted against Shannon entropy threshold focusing on the 
Shannon entropies between 1 and 1.1. 
 
Figure 4.6 shows that the optimum Shannon entropy threshold is 
1.04.Therefore an SNV with a Shannon entropy value at or below 1.04 can 
be considered as a candidate somatic driver SNV, while an SNV with a 
Shannon entropy value above 1.04 can be considered as a candidate 
somatic passenger SNV. 
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4.4 Conclusions 
The rapid growth in the whole genome sequencing of human cancers has 
opened up the opportunity to analyse and interpret the somatic SNVs that 
are present in TFBSs. Somatic driver SNVs in TFBSs tend to disrupt 
transcription factor binding leading to altered gene expression and 
consequently aiding cell proliferation and survival. Somatic passenger SNVs 
in TFBSs on the other hand do not disrupt transcription factor binding which 
in turn does not alter gene expression and therefore cell proliferation and 
survival would not be aided. Therefore there is a need to analyse the 
somatic driver and passenger SNVs in TFBSs.  
In this work, the analysis of a set of somatic driver and passenger SNVs in 
TFBSs also revealed that there were clear signals in terms of conservation 
and therefore Shannon Entropy value. Somatic driver SNVs were at 
positions within TFBSs that were more conserved and therefore had lower 
Shannon entropy values while somatic passenger SNVs were at positions 
within the TFBSs with low conservation and therefore had higher Shannon 
entropy values. This was subsequently exploited to identify the optimum 
Shannon entropy threshold value which could be used to prioritize candidate 
somatic driver SNVs in TFBSs.  
This work is potentially of immense value for the identification of novel 
somatic driver SNVs. This in turn will improve diagnosis and enable more 
personalised therapies. 
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5 Further Analysis of Somatic Driver 
and Passenger SNVs in TFBSs 
 
 
The aims of this chapter are: firstly, to identify the transcription factors whose 
TFBSs have mainly somatic driver or somatic passenger SNVs, secondly, to 
perform an analysis of the influence of the distance of the predicted precise 
TFBSs from the transcription start site on the type of somatic cancer SNVs 
(driver or passenger) in the TFBSs, thirdly, to perform an analysis of the 
location of the somatic driver and passenger SNVs in TFBSs, and finally to 
analyse the distribution of the somatic driver and passenger SNVs in TFBSs 
across the chromosomes. 
 
5.1 Introduction 
The recent advances in technologies for the massively parallel sequencing 
of DNA that allow sequencing of whole exomes and genomes have enabled 
the comprehensive characterisation of somatic driver and passenger SNVs 
across a large number of tumour samples (Watson et al., 2013).  In 
particular, the rise of whole genome sequencing of human cancers has 
opened up the opportunity to study the large numbers of somatic driver and 
passenger SNVs that occur in non-coding regions (Poulos et al., 2015a).   
Over 40% of all somatic SNVs occur in TFBSs, and somatic SNVs are 
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statistically enriched in TFBSs (P < 1 × 10−10, two-sided Fisher’s exact test) 
(Mathelier et al., 2015b; Melton et al., 2015). Somatic driver SNVs occurring 
in TFBSs have also been found to have the potential to disrupt the binding of 
transcription factors, thereby, altering the gene expression of the 
corresponding gene, and therefore, aiding the survival and proliferation of 
cancer cells (Mathelier et al., 2015c; Melton et al., 2015; Poulos et al., 
2015b). There is now a clear need to analyse somatic driver and passenger 
SNVs in TFBSs in order to understand the properties of somatic driver and 
passenger SNVs, therefore augmenting the biological interpretation of the 
mutational landscape of human cancers. 
In order to fulfil this need, large datasets of somatic driver and passenger 
SNVs in TFBSs, need to be obtained. In the previous chapter, a 
comprehensive set of predicted TFBSs was obtained by exploiting the 
results of the independent performance evaluations in chapters 2 and 3, 
which were carried out to identify the best performing pattern matching and 
motif discovery tools respectively to aid TFBS prediction. This set of 
predicted TFBSs was then used to obtain large datasets of somatic driver 
and passenger SNVs in TFBSs.  
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5.2 Identification of the Transcription Factors whose 
TFBSs contain almost exclusively Somatic Driver 
or Passenger SNVs  
 
The dataset of somatic driver and passenger SNVs (obtained as described 
in section 4.2.2) was examined to identify the transcription factors whose 
corresponding TFBSs contain: (i) the highest number of somatic driver SNVs 
and the lowest number of somatic passenger SNVs (ii) the transcription 
factors that have the highest number of somatic passenger SNVs and the 
lowest number of somatic driver SNVs. This was done using the UNIX 
command grep. 
The TFBSs corresponding to the transcription factors ERRA (an orphan 
nuclear receptor) and IRF1 (an interferon regulatory transcription factor) 
have the highest number of somatic driver SNVs (5115 and 6003 
respectively) and no somatic passenger SNVs. This is due to the fact that all 
of the genes that they regulate are all involved in the cell cycle, cell growth or 
apoptosis (Chang and McDonnell, 2012; Végran et al., 2014).  The TFBSs 
corresponding to the transcription factors PRDM1 (a zinc finger protein), and 
TAL1 (a basic helix-loop-helix transcription factor) have the lowest number of 
somatic driver SNVs (11 and 18 respectively), and the highest number of 
somatic passenger SNVs (5905 and 4993 respectively). This is due to the 
fact that the vast majority of the genes that they regulate are involved in the 
immune response, and only very few of the genes that they regulate are 
involved in the cell cycle (Minnich et al., 2016; Kassouf et al., 2010).   
140 
 
 
5.3 Analysis of the Influence of the Distance of the 
Predicted TFBSs from the Transcription Start Site 
on the Type of Somatic Cancer SNVs (Driver or 
Passenger) in the TFBSs 
 
The distance from the transcription start site of the predicted TFBSs that 
contain somatic driver and/or passenger SNVs were obtained from the 
datasets of somatic driver and passenger SNVs in TFBSs (obtained as 
described in section 4.2.2) using the UNIX command grep. 
A histogram of the distance from the transcription start site of the predicted 
TFBSs that contain somatic driver and/or passenger SNVs was plotted using 
the ggplot2 package (Wickham, 2009) in R (Team, 2014). This is shown in 
Figure 5.1 
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Figure 5.1: Distance from the transcription start site of the TFBSs containing 
somatic driver and passenger SNVs. 
 
Figure 5.1 strongly suggests that the distance from the transcription start site 
of the TFBSs has no influence on the type of somatic cancer SNV (driver or 
passenger) that occurs in a TFBS.  
Since the distributions are clearly not normal, a Mann-Whitney U test was 
performed in order to assess whether there was a significant difference 
between the distances from the transcription start site of the TFBSs 
containing somatic driver SNVs, and the distances from the transcription 
start site of the TFBSs containing somatic passenger SNVs. This was done 
using the wilcox.test function in R (Team, 2014) which defaults to the Mann-
Whitney U test.  
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The test statistic (𝑈𝑈) for the Mann-Whitney U test required to assess whether 
there was a significant difference between the distances from the 
transcription start site of the TFBSs containing somatic driver SNVs, and the 
distances from the transcription start site of the TFBSs containing somatic 
passenger SNVs, was then calculated by the wilcox.test function as follows: 
1. The distances from the transcription start site of the TFBSs containing 
somatic driver SNVs, and the distances from the transcription start 
site of the TFBSs containing somatic passenger SNVs were first 
pooled. 
2. The pooled set of distances were then sorted in ascending order, and 
assigned numerical ranks beginning with 1 for the smallest value.   
3. First, the ranks for the distances from the transcription start site of the 
TFBSs containing somatic driver SNVs were summed up. Then, the 
ranks for the distances from the transcription start site of the TFBSs 
containing somatic passenger SNVs were summed up. 
4. The 𝑈𝑈 statistic was then determined as follows:  
First, the 𝑈𝑈 statistic was calculated for the distances from the 
transcription start site of the TFBSs containing somatic driver SNVs. 
This is denoted as 𝑈𝑈1. 
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𝑈𝑈1 =  𝐹𝐹1 −  𝑆𝑆1   (𝑆𝑆1   + 1 )2      (5.1) 
Where, 𝑆𝑆1 is the number of somatic driver SNVs, and, 𝐹𝐹1 is the sum of the 
ranks for the distances from the transcription start site of the TFBSs 
containing somatic driver SNVs 
Then, the 𝑈𝑈 statistic was calculated for the distances from the transcription 
start site of the TFBSs containing somatic passenger SNVs. This is denoted 
as 𝑈𝑈2. 
 
𝑈𝑈2 =  𝐹𝐹2 −  𝑆𝑆2 (𝑆𝑆2 + 1)2       (5.2) 
 
Where, 𝑆𝑆2 is the number of somatic passenger SNVs and, 𝐹𝐹2 is the sum of 
the ranks for the distances from the transcription start site of the TFBSs 
containing somatic passenger SNVs 
The smaller value of 𝑈𝑈1 and 𝑈𝑈2 was then used to assess significance.  
 
For the Mann-Whitney U test, the possible values of 𝑈𝑈 range from 0 
(resulting in a very significant difference between the distances from the 
transcription start site of the TFBSs containing somatic driver SNVs, and the 
distances from the transcription start site of the TFBSs containing somatic 
passenger SNVs) to 𝑆𝑆1 * 𝑆𝑆2, which in this case, is 72329 * 87572  which 
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equals 6333995188 ( resulting in no significant difference at all between the 
distances from the transcription start site of the TFBSs containing somatic 
driver SNVs, and the distances from the transcription start site of the TFBSs 
containing somatic passenger SNVs) (Krzywinski and Altman, 2014; Team, 
2014). 
As expected from a visual inspection of Figure 5.1, the Mann-Whitney U test 
showed no significant difference in the distances from the transcription start 
site of the TFBSs containing somatic driver SNVs, and the distances from 
the transcription start site of the TFBSs containing somatic passenger SNVs 
with a 𝑈𝑈 statistic of 3.156 x 109, and a p-value of 0.2163.  
These results confirm that the distance from the transcription start site of the 
TFBSs has no influence on the type of somatic cancer SNV (driver or 
passenger) that occurs in a TFBS. 
 
5.4 Analysis of the Location of the Somatic Driver 
and Passenger SNVs in TFBSs 
The positions of the somatic driver and passenger SNVs in TFBSs were 
obtained from the datasets of somatic driver and passenger SNVs in TFBSs 
(obtained as described in section 4.2.2) using the UNIX command grep. 
A histogram of the positions of the somatic driver and passenger SNVs 
within the TFBSs was then plotted using the ggplot2 package (Wickham, 
2009) in R (Team, 2014). This is shown in Figure 5.2. 
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Figure 5.2: Location of the somatic driver and passenger SNVs within the TFBSs 
 
Figure 5.2 strongly suggests that the somatic driver and passenger SNVs do 
not occur in a specific location within the TFBSs. 
Since the distributions are clearly not normal, a Mann-Whitney U test was 
performed in order to assess whether there was a significant difference 
between the location of the somatic driver SNVs within the TFBSs, and the 
location of the somatic passenger SNVs within the TFBSs. This was done 
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using the wilcox.test function in R (Team, 2014) which defaults to the Mann-
Whitney U test.  
The test statistic (𝑈𝑈) for the Mann-Whitney U test required to assess whether 
there was a significant difference between the location of the somatic driver 
SNVs within the TFBSs, and the location of the somatic passenger SNVs 
within the TFBSs, was then calculated by the wilcox.test function as follows: 
1. The locations of the somatic driver SNVs within the TFBSs, and the 
locations of the somatic passenger SNVs within the TFBSs were first 
pooled. 
2. The pooled set of locations were then sorted in ascending order, and 
assigned numerical ranks beginning with 1 for the smallest value.   
3. First, the ranks for the locations of the somatic driver SNVs within the 
TFBSs were summed up. Then, the ranks for the locations of the 
somatic passenger SNVs within the TFBSs were summed up. 
4. The 𝑈𝑈 statistic was then determined as follows:  
First, the 𝑈𝑈 statistic was calculated for the locations of the somatic 
driver SNVs within the TFBSs.  This is denoted as 𝑈𝑈1. 
 
𝑈𝑈1 =  𝐹𝐹1 −  𝑆𝑆1   (𝑆𝑆1   + 1 )2       (5.3) 
Where, 𝑆𝑆1 is the number of somatic driver SNVs, and, 𝐹𝐹1 is the sum of the 
ranks for the locations of the somatic driver SNVs within the TFBSs 
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Then, the 𝑈𝑈 statistic was calculated for the locations of the somatic 
passenger SNVs within the TFBSs. This is denoted as 𝑈𝑈2. 
 
𝑈𝑈2 =  𝐹𝐹2 −  𝑆𝑆2 (𝑆𝑆2 + 1)2     (5.4) 
 
Where, 𝑆𝑆2 is the number of somatic passenger SNVs, and, 𝐹𝐹2 is the sum of 
the ranks for the locations of the somatic passenger SNVs within the TFBSs. 
The smaller value of 𝑈𝑈1 and 𝑈𝑈2 was then used to assess significance.  
 
For the Mann-Whitney U test, the possible values of 𝑈𝑈 range from 0 
(resulting in a very significant difference between the location of the somatic 
driver SNVs within the TFBSs, and the location of the somatic passenger 
SNVs within the TFBSs) to 𝑆𝑆1 * 𝑆𝑆2, which in this case is again 72329 * 
87572  which equals 6333995188 ( resulting in no significant difference at all 
between the location of the somatic driver SNVs within the TFBSs, and the 
location of the somatic passenger SNVs within the TFBSs) (Krzywinski and 
Altman, 2014; Team, 2014). 
 
As expected from a visual inspection of Figure 5.2, the Mann-Whitney U test 
showed no significant difference in the location of the somatic driver SNVs 
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within the TFBSs, and the location of the somatic passenger SNVs within the 
TFBSs with a 𝑈𝑈 statistic of 3.177 x 109, and a p-value of 0.2699.  
These results confirm that somatic driver and passenger SNVs do not occur 
in specific locations within the TFBSs. 
5.5 Analysis of the Distribution of the TFBSs across 
the Chromosomes 
In order to analyse the distribution of the somatic driver and passenger 
SNVs in TFBSs across the chromosomes, it is necessary to first analyse the 
distribution of the TFBSs across the chromosomes.  This is because the 
distribution of the TFBSs across the chromosomes may underpin the 
distribution of the somatic driver and passenger SNVs in TFBSs across the 
chromosomes. 
The chromosomal location of the TFBSs were obtained from the set of 
predicted TFBSs (obtained as described in section 4.2.1) using the UNIX 
command grep. A bar chart showing the distribution of the TFBSs across the 
chromosomes was then plotted using R (Team, 2014). This is shown in 
Figure 5.3. 
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Figure 5.3: Distribution of the TFBSs across the chromosomes 
 
Figure 5.3 strongly suggests that the TFBSs are not equally distributed 
across the chromosomes.  
A one sample chi-squared test was then performed in order to assess 
whether the observed distribution of TFBSs across the chromosomes was 
statistically different from the distribution of TFBSs across the chromosomes 
expected by chance. This was done using the chisq.test function in R (Team, 
2014). This was chosen because there is only one categorical variable with 
the data in the form of frequencies falling into mutually exclusive categories.   
As expected from a visual inspection of Figure 5.3, the one sample chi-
squared test showed that the observed distribution of TFBSs across the 
chromosomes is statistically very different from the distribution of TFBSs 
across the chromosomes expected by chance with a chi-squared statistic of  
22507 at 23 degrees of freedom and a p-value of < 2.2 x 10-16. 
These results confirm that the TFBSs are not equally distributed across the 
chromosomes. 
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This is because, the number of genes in each chromosome has been found 
to vary with higher numbers of TFBSs found in chromosomes that are more 
gene-rich (i.e. have a higher number of genes) (Thévenin et al., 2014).  The 
highest numbers of TFBSs are found in chromosome 1 which has the 
highest number of genes, while the lowest numbers of TFBSs are found in 
the Y chromosome which has the lowest number of genes (Gregory et al., 
2006; Skaletsky et al., 2003).  
5.6 Analysis of the Distributions of the Somatic 
Driver and Passenger SNVs in TFBSs across the 
Chromosomes 
 
The chromosomal location of the somatic driver and passenger SNVs in 
TFBSs were obtained from the datasets of somatic driver and passenger 
SNVs in TFBSs (obtained as described in section 4.2.2) using the UNIX 
command grep. A bar chart showing the distribution of the somatic driver 
and passenger SNVs in TFBSs across the chromosomes was then plotted 
using R (Team, 2014). This is shown in Figure 5.4. 
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Figure 5.4: Distribution of the somatic driver and passenger SNVs in TFBSs across 
the chromosomes  
 
Figure 5.4 suggests that the distribution of the somatic driver SNVs in TFBSs 
across the chromosomes does not differ from the distribution of the somatic 
passenger SNVs in TFBSs across the chromosomes.  
Figure 5.4 also shows that the somatic driver and passenger SNVs in TFBSs 
are not equally distributed across the chromosomes.  Comparison of Figure 
5.3 and Figure 5.4 shows that higher numbers of somatic driver and 
passenger SNVs are present in chromosomes with higher numbers of 
TFBSs.  Therefore, the distribution of the somatic driver and passenger 
SNVs across the chromosomes is underpinned by the distribution of the 
TFBSs across the chromosomes. Hence chromosome 1 has the highest 
number of somatic driver and passenger SNVs in TFBSs and the Y 
chromosome has the lowest numbers of somatic driver and passenger SNVs 
in TFBSs.  
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A two sample chi-squared test was then performed in order to assess 
whether the distribution of somatic driver SNVs in TFBSs across the 
chromosomes was statistically different to the distribution of somatic 
passenger SNVs in TFBSs across the chromosomes. This was done using 
the chisq.test function in R (Team, 2014). This was chosen because there 
are two categorical variables with multiple possible values.   
As expected from a visual inspection of Figure 5.4, the two sample chi-
squared test showed the distribution of somatic driver SNVs in TFBSs 
across the chromosomes is statistically not different to the distribution of 
somatic passenger SNVs in TFBSs across the chromosomes with a chi-
squared statistic of 552 at 23 degrees of freedom and a p-value of 0.2365. 
These results confirm that the distribution of the somatic driver SNVs in 
TFBSs across the chromosomes is not different from the distribution of 
somatic passenger SNVs in TFBSs across the chromosomes. 
5.7 Conclusions 
The rapid growth in the whole genome sequencing of human cancers has 
opened up the opportunity to analyse and interpret the somatic driver and 
passenger SNVs that are present in TFBSs.  
In this work: (i)  the TFBSs corresponding to the transcription factors ERRA 
and IRF1 were found to have only somatic driver SNVs and no somatic 
passenger SNVs, while the TFBSs corresponding to the transcription factors 
PRDM1 and TAL1 were found to have the lowest number of somatic driver 
SNVs and the highest number of somatic passenger SNVs. 
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(ii) The analysis of a set of somatic driver and passenger SNVs in TFBSs 
revealed that the distance from the transcription start site of the TFBSs has 
no influence on the type of somatic cancer SNV (driver or passenger) that 
occurs in a TFBS. (iii) The analysis of a set of somatic driver and passenger 
SNVs in TFBSs also revealed that somatic driver and passenger SNVs do 
not occur in specific locations within the TFBSs. (iv) The analysis of the 
distribution of somatic driver and passenger SNVs in TFBSs across the 
chromosomes also revealed that the distribution of the somatic driver SNVs 
in TFBSs across the chromosomes is not different from the distribution of the 
somatic passenger SNVs in TFBSs across the chromosomes and that higher 
numbers of somatic driver and passenger SNVs are present in 
chromosomes with higher numbers of TFBSs. 
Therefore, this work suggests that analysis of somatic driver and passenger 
SNVs in TFBSs is key to interpreting the mutational landscape of human 
cancers, which in turn will yield novel insight into malignant phenotypes. This 
in turn will improve diagnosis and enable more personalised therapies. 
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6 Conclusions 
6.1 The Prediction of TFBSs 
The coupling of SNVs identified through whole genome sequencing with the 
publicly available ChIP-Seq regions that have resulted from the ENCODE 
project provides the opportunity to reveal novel SNVs that occur in TFBSs, 
which cause inherited diseases, and act as driver SNVs in cancer. In the 
long term, this will assist in improving the diagnosis of inherited diseases 
(where 30-50% of causal SNVs are missed), and will improve the diagnosis 
of, and aid in more personalised therapies for, cancer (Fratkin et al., 2012).  
The ENCODE ChIP-Seq regions are much longer than the precise binding 
site for a particular transcription factor, and therefore, the precise binding site 
still needs to be detected. This needs to be done by the computational 
prediction of TFBSs, as there are a limited number of experimentally 
characterised TFBSs available.  
There are two components to the computational prediction of TFBSs: a 
PWM and a pattern matching tool (Worsley-Hunt et al., 2011).  
PWMs are derived using motif discovery tools of which many are available. 
Some of these motif discovery tools have the capability to handle large 
volumes of data, while others do not. Motif discovery tools exist in both 
online and locally-installable forms. Only the locally-installable versions of 
the motif discovery tools that have the capacity to handle large volumes of 
data can be used, given the sheer volume of ChIP-Seq data that has 
resulted from the ENCODE project.   
155 
 
As with the motif discovery tools, pattern matching tools exist in both online 
and locally-installable forms. However, just as with motif discovery, only the 
locally-installable versions can be used given the sheer volume of ChIP-Seq 
data that has resulted from the ENCODE project. 
Several locally-installable pattern matching tools and motif discovery tools 
that are able to handle large volumes of data have been developed. 
However, to date, there has not been an independent performance 
evaluation of these tools. 
In chapter 2, an independent evaluation of a set of open source and locally- 
installable pattern matching tools that predict both individual TFBSs and 
clusters of TFBSs was carried out. The pattern matching tools that predict 
individual TFBSs were found to outperform the pattern matching tools that 
predict clusters of TFBSs. The pattern matching tool that was found to have 
the best performance was FIMO (Grant et al., 2011). The performance 
evaluation of the pattern matching tools was done before the evaluation of 
the motif discovery tools because, the evaluation of the performance of motif 
discovery methods requires a pattern matching tool to test the performance 
of the resulting PWMs. Therefore, a pattern matching tool must be selected 
for this purpose.  
In chapter 3 an independent assessment of a set of open source and locally- 
installable motif discovery tools that are able to handle the large volumes of 
data that have arisen from the ENCODE project was carried out.  The motif 
discovery tool rGADEM (Mercier et al., 2011) was found to have the best 
performance. A new set of PWMs were then generated using rGADEM. This 
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new set of PWMs was named hCRM and has been made publicly available 
for free download (http://www.bioinf.org.uk/tfbs/).  The set of pattern 
matching tools that were evaluated in chapter 2 were re-evaluated using the 
hCRM PWMs in order to check that the selection of the best pattern 
matching tool is not unduly influenced by the choice of PWMs.   The pattern 
matching tool FIMO was still the best performing and the overall ranking of 
tools remained the same. However, the use of the hCRM PWMs (which were 
derived from ChIP-Seq data)  to evaluate the pattern matching tools gave a 
better performance in comparison to evaluation of the pattern matching tools 
that made use of the JASPAR.2010 PWMs (which were derived from SELEX 
or individual promoter assays).  
 
6.2 Application of TFBS Prediction to analyse non-
coding somatic cancer SNVs  
In recent years, there has been a huge increase in the number of somatic 
cancer non-coding SNVs that have been identified due to the rise in whole 
genome sequencing of human cancers. This presents a unique opportunity 
to analyse the somatic driver and passenger SNVs in TFBSs and to exploit 
the results of the analyses to develop an approach to the prioritization of 
somatic non-coding cancer driver SNVs that occur in TFBSs for 
experimental validation (Watson et al., 2013).  Chapter 4 focusses on 
analysing the conservation of the positions of somatic non-coding cancer 
driver and passenger SNVs in TFBSs and exploiting the results of the 
analysis to help prioritize somatic cancer driver in TFBSs. A more 
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comprehensive prediction of TFBSs was first done by exploiting the analyses 
in chapters 2 and 3. This was then followed by an analysis of the 
conservation of the positions of the driver and passenger SNVs occurring in 
TFBSs, which revealed that the driver SNVs tended to be at positions within 
TFBSs that are more conserved, and therefore, have low Shannon entropies 
while the passenger SNVs tended to be at positions within the TFBSs with 
low conservation and therefore have high Shannon entropies. The observed 
differences in the Shannon entropies of the somatic driver and passenger 
SNVs was exploited to prioritize somatic driver SNVs in TFBSs by identifying 
the optimum Shannon entropy threshold for distinguishing between driver 
and passenger SNVs. The optimum threshold was found to be 1.04 but no 
somatic driver SNVs were identified with a Shannon entropy of >1.3 and no 
somatic passenger SNVs were identified with a Shannon entropy of <0.8. 
Chapter 5 focusses on the further analysis of the large datasets of somatic 
cancer driver and passenger SNVs collected in chapter 4. First, the 
transcription factors whose TFBSs have mainly somatic driver or somatic 
passenger were identified. This revealed that the TFBSs corresponding to 
the transcription factors ERRA and IRF1 were found to have only somatic 
driver SNVs and no somatic passenger SNVs, while the TFBSs 
corresponding to the transcription factors PRDM1 and TAL1 were found to 
have the lowest number of somatic driver SNVs and the highest number of 
somatic passenger SNVs. 
Second, an analysis of the influence of the distance of the predicted precise 
TFBSs from the transcription start site on the type of somatic cancer SNVs 
(driver or passenger) in the TFBSs was performed, which revealed that the 
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distance from the transcription start site of the TFBSs has no influence on 
the type of somatic cancer SNV (driver or passenger) that occurs in a TFBS.  
Third, an analysis of the location of the somatic driver and passenger SNVs 
within the TFBSs, which revealed that somatic driver and passenger SNVs 
do not occur in specific locations within the TFBSs. Finally, an analysis of the 
distribution of the somatic driver and passenger SNVs in TFBSs across the 
chromosomes was performed which revealed that the distribution of the 
somatic driver SNVs in TFBSs across the chromosomes is not different from 
the distribution of the somatic passenger SNVs in TFBSs across the 
chromosomes and that higher numbers of somatic driver and passenger 
SNVs are present in chromosomes with higher numbers of TFBSs. 
 
6.3 Future Work 
6.3.1 More Complex models 
The PWM model is the most widely used model for TFBS prediction. 
However, the PWM model, is limited by its assumption that positions within a 
binding site are independent, something which is not true in all cases as it 
has been found that nucleotide interdependencies can exist (Nguyen and 
Androulakis, 2009; Hannenhalli, 2008). 
Recently, more complex alternatives to the PWM model that take into 
account nucleotide interdependencies have been developed. These more 
complex alternatives are the  “transcription factor flexible models” (TFFM) 
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(Mathelier and Wasserman, 2013) and “Dinucleotide PWMs” (Kulakovskiy et 
al., 2013a).  
It has been found that more complex models do not outperform PWMs for 
the vast majority of transcription factors. However, for a small number of 
individual transcription factors e.g. REST , it has been suggested that the 
usage of more complex models could result in better performance (Weirauch 
et al., 2013). Thus, in future, it may be worth evaluating PWMs, TFFMs and 
dinucleotide PWMs and selecting an appropriate model for each of these 
individual transcription factors. 
6.3.2 Application of TFBS prediction to non-coding SNVs 
causing inherited diseases 
There are currently very few examples of germline non-coding SNVs that 
have been found to cause inherited diseases (Heibel et al., 2011; Ludlow et 
al., 1996; Reijnen et al., 1992; van Wijk et al., 2003; Manco et al., 2000). 
Whole genome sequencing is currently being carried out for many inherited 
diseases on a large scale (e.g. the UK100K project). As a result, a large 
amount of germline non-coding SNVs that cause inherited diseases is 
expected to become available in the next few years. Similarly to the work 
done in chapter 4, the predicted TFBSs can be used to identify germline 
non-coding inherited disease causing SNVs in TFBSs. An analysis of the 
Shannon entropy values of these SNVs and the Shannon entropy values of 
a set of common SNVs (occurring in >1% of the population) that have been 
obtained from dbSNP could then be carried out. The results of this analysis 
could then be exploited to prioritize non coding inherited disease causing 
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SNVs in TFBSs by identifying the optimum Shannon entropy threshold for 
distinguishing between inherited disease causing and neutral SNVs.   
6.3.3 Identifying Functional Effects of Non-coding Somatic 
Cancer SNVs That Occur in CRMs 
In order to identify the functional effects (i.e. driver or passenger) of non-
coding somatic cancer SNVs that occur in CRMs, the CRMs need to be 
computationally predicted. This is because, there are no experimentally 
validated sets of human CRMs. The computational prediction of CRMs is 
done by using pattern matching tools that identify clusters of TFBSs.  
In order to predict CRMs computationally, it is essential to know what 
transcription factors bind cooperatively. This information is not available at 
the moment, but large volumes of high-throughput biochemical data are 
currently being collected by multiple laboratories in order to identify what 
human transcription factors bind cooperatively. As a result a large amount of 
information revealing what human transcription factors bind cooperatively is 
expected to become publically available soon (Hardison and Taylor, 2012; 
Suryamohan and Halfon, 2015).  
With the availability of this information, CRMs can then be predicted using 
MCAST  which was identified as the best performing pattern matching tool 
that predicts clusters of TFBSs in chapter 2. The predicted CRMs could then 
be used to identify non-coding somatic cancer SNVs that occur in CRMs, 
and the Shannon entropy based prioritization from chapter 4 could then be 
adapted to identify the functional effects (i.e. driver or passenger) of non-
coding somatic cancer SNVs that occur in a CRM. 
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Appendix A  File formats  
 
A.1 The FASTQ format 
The FASTQ format is a plain text format for representing nucleotide 
sequences together with their associated quality scores. The FASTQ format 
consists of four records per entry. The first record begins with a ‘@’ 
character, and is followed by the sequence identifier and optionally a 
description. The second record consists of the sequence which can be split 
across multiple lines. The third record begins with a ‘+’ character and is 
followed optionally by a repeat of the first record (excluding the ‘@’ 
character). The fourth record consists of the quality scores and must be the 
same length as the second record (the sequence). These quality scores 
range from the ‘!’ character (representing the lowest quality) to ‘~’ 
(representing the highest quality). The fourth record can also be split across 
multiple lines. (Cock et al., 2010). The FASTQ format is illustrated in Figure 
A.1.1. 
@SRR014849.1 EIXKN4201CFU84 length=93 
GGGGGGGGGGGGGGGGCTTTTTTTGTTTGGAACCGAAAGG 
GTTTTGAATTTCAAACCCTTTTCGGTTTCCAACCTTCCAA 
AGCAATGCCAATA 
+SRR014849.1 EIXKN4201CFU84 length=93 
3+&$#"""""""""""7F@71,’";C?,B;?6B;:EA1EA 
1EA5’9B:?:#9EA0D@2EA5’:>5?:%A;A8A;?9B;D@ 
/=<?7=9<2A8== 
      
Figure A.1.1: An example of the FASTQ format. 
 
A.2 The SAM format  
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The SAM format is a plain text format for storing read alignments. All lines 
are tab delimited. The SAM format consists of two sections: a header 
section, and an alignment section with each line in the header section 
beginning with a ‘@’ character. Each line in the alignment section has eleven 
compulsory fields. The compulsory fields are:  
1. the read name 
2. a bitwise flag providing extra information about the read 
3. the reference sequence name 
4. the chromosome name 
5. the position of the first matching base  
6. the mapping quality score 
7. a string describing the pairwise alignment (this string reports the 
number of mismatches (‘M’), the number of insertions (‘I’), the number 
of deletions (‘D’), the number of skipped bases (‘N’), the number of 
bases not in the alignment which have been retained in the sequence 
(‘S’), the number of bases not in the alignment which have been 
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excluded from the sequence (‘H’) and if the read has been fully 
aligned (‘P’))   
8. the chromosome name of the next read (which is reported with an ‘=’ 
character if it is the same chromosome as the previous read) 
9. position of the next read, the inferred insert size (approximate size of 
any insertions and deletions with deletions reported as negative 
numbers) 
10. the sequence  
11. the base quality score 
 
Any unavailable information is represented with a ‘*’ character or a zero (Li 
et al., 2009b). The SAM format is illustrated in Figure A.2.1. 
@SQ SN:ref LN:45 
r001 163 ref 7 30 8M2I4M1D3M = 37 39 TTAGATAAAGGATACTA * 
r002 0 ref 9 30 3S6M1P1I4M * 0 0 AAAAGATAAGGATA * 
r003 0 ref 9 30 5H6M * 0 0 AGCTAA * NM:i:1 
r004 0 ref 16 30 6M14N5M * 0 0 ATAGCTTCAGC * 
r003 16 ref 29 30 6H5M * 0 0 TAGGC * NM:i:0 
r001 83 ref 37 30 9M = 7 ‐39 CAGCGCCAT * 
 
Figure A.2.1: An example of the SAM format.  
 
 
A.3 The VCF format  
The VCF format is a plain text format for storing SNV data. It consists of two 
sections: a header section and a data section. The header section consists 
of a number of meta-information lines with each one prefixed by the 
characters ‘##’. These meta-information lines describe the tags and 
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annotations used in the data section as well as file creation information, 
reference genome version, software used to call SNVs and any other 
relevant information. The header section also contains a tab delimited field 
definition line which is prefixed by the character ‘#’. The field definition line 
names the eight compulsory fields. These are:  
1. the chromosome (CHROM) 
2. the position (POS) 
3. the unique identifier (ID) 
4. the reference allele (REF) 
5. the mutation (ALT) 
6. the quality score (QUAL) 
7. filtering information (FILTER)  
8. annotations (INFO) 
The data section contains the data that correspond to the above fields. The 
lines in the data section are tab delimited and must match the number of 
fields defined in the header section (Danecek et al., 2011). The VCF format 
is illustrated in Figure A.3.1.      
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##fileformat=VCFv4.0 
##fileDate=20090805 
##source=VCFTools 
##reference=1000GenomesPilot-NCBI36 
 
##INFO=<ID=NS,Number=1,Type=Integer,Description="Number of Samples 
With Data"> 
##INFO=<ID=DP,Number=1,Type=Integer,Description="Total Depth"> 
##INFO=<ID=AF,Number=.,Type=Float,Description="Allele Frequency"> 
##INFO=<ID=AA,Number=1,Type=String,Description="Ancestral Allele"> 
##INFO=<ID=DB,Number=0,Type=Flag,Description="dbSNP membership, 
build 129"> 
##INFO=<ID=H2,Number=0,Type=Flag,Description="HapMap2 membership"> 
##FILTER=<ID=q10,Description="Quality below 10"> 
##FILTER=<ID=s50,Description="Less than 50% of samples have data"> 
##FORMAT=<ID=GT,Number=1,Type=String,Description="Genotype"> 
##FORMAT=<ID=GQ,Number=1,Type=Integer,Description="Genotype 
Quality"> 
##FORMAT=<ID=DP,Number=1,Type=Integer,Description="Read Depth"> 
##FORMAT=<ID=HQ,Number=2,Type=Integer,Description="Haplotype 
Quality"> 
#CHROM POS     ID        REF ALT    QUAL FILTER    INFO                               
20     14370   rs6054257 G    A    29   PASS         .   
20     17330   .         T    A    3    q10          .      
20     1110696 rs6040355 A   G,T   67   PASS         .    
20     1230237 .         T      .  47   PASS   NS=3;DP=13;AA=T                   
20     1234567 microsat1 GTCT G,GTACT 50 PASS   NS=3;DP=9;AA=G                     
 
Figure A.3.1: An example of the VCF format. 
 
A.4 PWM file formats 
 
A.4.1 MEME  
The pattern matching tools FIMO and MCAST require the PWMs to be in 
MEME file format. The MEME format illustrated in Figure A.4.1 is a plain text 
format which contains the following sections:  
1. the MEME version line which details the oldest version of MEME-
SUITE that the file can be read by 
2. an alphabet line detailing whether the PWM is for DNA or protein 
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3. a line giving information on the background frequencies in the source 
sequence 
4. a line giving the name of the motif 
5. a line giving information on the alphabet length (this is 4 if the PWM is 
for a DNA sequence and 20 if it is for a protein sequence) and the 
width of the PWM  
6. a set of records containing the PWM itself. Each row represents the 
four bases and adds up to one.  
 
MEME version 4 
 
ALPHABET= ACGT 
 
 
 
Background letter frequencies 
A 0.303 C 0.183 G 0.209 T 0.306  
 
MOTIF crp 
letter-probability matrix: alength= 4 w= 19  
 0.000000  0.176471  0.000000  0.823529  
 0.000000  0.058824  0.647059  0.294118  
 0.000000  0.058824  0.000000  0.941176  
 0.176471  0.000000  0.764706  0.058824  
 0.823529  0.058824  0.000000  0.117647  
 0.294118  0.176471  0.176471  0.352941  
 0.294118  0.352941  0.235294  0.117647  
 0.117647  0.235294  0.352941  0.294118  
 0.529412  0.000000  0.176471  0.294118  
 0.058824  0.235294  0.588235  0.117647  
 0.176471  0.235294  0.294118  0.294118  
 0.000000  0.058824  0.117647  0.823529  
 0.058824  0.882353  0.000000  0.058824  
 0.764706  0.000000  0.176471  0.058824  
 0.058824  0.882353  0.000000  0.058824  
 0.823529  0.058824  0.058824  0.058824  
 0.176471  0.411765  0.058824  0.352941  
 0.411765  0.000000  0.000000  0.588235  
 0.352941  0.058824  0.000000  0.588235  
 
 
Figure A.4.1: An example of the MEME format. 
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A.4.2 Cluster-Buster 
The pattern matching tools Cister, Cluster-Buster, Comet and Clover require 
the PWM to be in Cluster-Buster format. The Cluster-Buster format shown in 
Figure A.4.2 is a FASTA –like file format for representing PWMs, consisting 
of a FASTA header line followed by the PWM itself. Each row represents the 
4 bases (in the order ACGT) and adds up to one.   
> crp 
 0.000000  0.176471  0.000000  0.823529  
 0.000000  0.058824  0.647059  0.294118  
 0.000000  0.058824  0.000000  0.941176  
 0.176471  0.000000  0.764706  0.058824  
 0.823529  0.058824  0.000000  0.117647  
 0.294118  0.176471  0.176471  0.352941  
 0.294118  0.352941  0.235294  0.117647  
 0.117647  0.235294  0.352941  0.294118  
 0.529412  0.000000  0.176471  0.294118  
 0.058824  0.235294  0.588235  0.117647  
 0.176471  0.235294  0.294118  0.294118  
 0.000000  0.058824  0.117647  0.823529  
 0.058824  0.882353  0.000000  0.058824  
 0.764706  0.000000  0.176471  0.058824  
 0.058824  0.882353  0.000000  0.058824  
 0.823529  0.058824  0.058824  0.058824  
 0.176471  0.411765  0.058824  0.352941  
 0.411765  0.000000  0.000000  0.588235  
 0.352941  0.058824  0.000000  0.588235  
 
Figure A.4.2: An example of the Cluster-Buster format. 
 
A.4.3 TRANSFAC 
The pattern matching tools Patch, Match and Matrixcatch require the PWMs 
to be in TRANSFAC format, a plain text format for representing PWMs as 
shown in Figure A.4.3. It contains the following sections:  
1. an AC line containing a unique accession code 
2. an ID line containing a unique identifier 
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3. a header row beginning with ‘P0’ containing the order of the bases  
4. the PWM itself with each record beginning with a 2-digit position 
number 
Blank rows begin with ‘XX’.   
 
AC U00001 
XX 
ID V$CRP 
XX 
P0     A         C            G     T 
01 0.000000  0.176471  0.000000  0.823529  
02 0.000000  0.058824  0.647059  0.294118  
03 0.000000  0.058824  0.000000  0.941176  
04 0.176471  0.000000  0.764706  0.058824  
05 0.823529  0.058824  0.000000  0.117647  
06 0.294118  0.176471  0.176471  0.352941  
07 0.294118  0.352941  0.235294  0.117647  
08 0.117647  0.235294  0.352941  0.294118  
09 0.529412  0.000000  0.176471  0.294118  
10 0.058824  0.235294  0.588235  0.117647  
11 0.176471  0.235294  0.294118  0.294118  
12 0.000000  0.058824  0.117647  0.823529  
13 0.058824  0.882353  0.000000  0.058824  
14 0.764706  0.000000  0.176471  0.058824  
15 0.058824  0.882353  0.000000  0.058824  
16 0.823529  0.058824  0.058824  0.058824  
17 0.176471  0.411765  0.058824  0.352941  
18 0.411765  0.000000  0.000000  0.588235  
19 0.352941  0.058824  0.000000  0.588235 
XX 
// 
Figure A.4.3: An example of the TRANSFAC format. 
 
A.4.4 PoSSuM-PSSM 
The pattern matching tool PoSSuMsearch requires the PWMs to be in 
PoSSuM-PSSM format, a plain text format shown in Figure A.4.4. It contains 
the following sections stored between two lines- BEGIN and END:  
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1. an ID line containing the identifier for the PWM 
2. an AC line containing the accession for the PWM 
3. a DE line describing the PWM 
4. an AP line detailing whether the PWM is for DNA or protein 
5. an LE line specifying the number of rows of the PWM followed by the 
PWM itself 
The order of the bases is introduced by a ‘#’ and the PWM matrix lines start 
with ‘MA’.  
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BEGIN  
ID V$CRP  
AC U00001 
DE CRP 
AP DNA 
LE 19 
#     A      T       C      G 
MA 0.000000  0.176471  0.000000  0.823529  
MA 0.000000  0.058824  0.647059  0.294118  
MA 0.000000  0.058824  0.000000  0.941176  
MA 0.176471  0.000000  0.764706  0.058824  
MA 0.823529  0.058824  0.000000  0.117647  
MA 0.294118  0.176471  0.176471  0.352941  
MA 0.294118  0.352941  0.235294  0.117647  
MA 0.117647  0.235294  0.352941  0.294118  
MA 0.529412  0.000000  0.176471  0.294118  
MA 0.058824  0.235294  0.588235  0.117647  
MA 0.176471  0.235294  0.294118  0.294118  
MA 0.000000  0.058824  0.117647  0.823529  
MA 0.058824  0.882353  0.000000  0.058824  
MA 0.764706  0.000000  0.176471  0.058824  
MA 0.058824  0.882353  0.000000  0.058824  
MA 0.823529  0.058824  0.058824  0.058824  
MA 0.176471  0.411765  0.058824  0.352941  
MA 0.411765  0.000000  0.000000  0.588235  
MA 0.352941  0.058824  0.000000  0.588235  
 
END 
 
Figure A.4.4: An example of the PoSSuM-PSSM format. 
A.4.5 tab 
The pattern matching tools Patser and BayCis require the PWMs to be in tab 
format as shown in Figure A.4.5. This represents the PWM as a tab 
delimited file with a header line introduced by a semi-colon followed by the 
PWM itself. Each row of the PWM is preceded by A, T, C and G, and 
separated from the values by a pipe symbol. Each PWM record is ended 
with two slashes.  The tab format has PWM positions across a line and rows 
representing the bases. This is in contrast to all the preceding matrix formats 
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that have the four bases going across a line with the rows representing the 
PWM positions.  
; MET4 matrix, from Gonze et al. (2005). Bioinformatics 21, 3490-
500. 
A |   7   9   0   0  16   0   1   0   0  11   6   9   6   1   8 
C |   5   1   4  16   0  15   0   0   0   3   5   5   0   2   0 
G |   4   4   1   0   0   0  15   0  16   0   3   0   0   2   0 
T |   0   2  11   0   0   1   0  16   0   2   2   2  10  11   8 
// 
 
Figure A.4.5: An example of the tab format. 
 
 The pattern matching tool matrix-scan is much more flexible regarding the 
format of the PWMs and accepts PWMs in MEME, Cluster-Buster, tab and 
TRANSFAC formats as well as the native JASPAR format (which is 
discussed below).    
A.4.6 JASPAR  
The JASPAR format is a plain text file format shown in Figure A.4.6 for 
representing PWMs. Similarly, to the tab format each row of the PWM is 
preceded by A, T, C and G and separated from the values by a pipe symbol. 
The JASPAR format has PWM positions across a line and rows, 
representing the bases.  
A|  0  3 79 40 66 48 65 11 65  0 
C| 94 75  4  3  1  2  5  2  3  3 
G|  1  0  3  4  1  0  5  3 28 88 
T|  2 19 11 50 29 47 22 81  1  6 
   
Figure A.4.6: An example of the JASPAR format. 
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A.5 The GFF format 
The GFF format shown in Figure A.5.1 is a tab separated file format used for 
storing genomic information. The first line of the file, consists of a comment 
identifying the file format, and version. This is followed by a set of lines 
describing the data.  Each line contains the following fields:  
1. the chromosome name  
2. the source name 
3. the feature name 
4. the start position 
5. the end position 
6. the score of the feature 
7. the strand  
8. the attributes (a semicolon separated list of key-value pairs that 
provide additional information) 
A ‘.’ character is used to represent any empty fields.  
##gff-version 3 
1  .  TFBS  1300  1315  .  +   ID=TFBS00001 
1  .  TFBS  1050  1060  .  +   ID=TFBS00002 
1  .  TFBS  3000  3012  .  +   ID=TFBS00003 
1  .  TFBS  5000  5014  .  +   ID=TFBS00004 
1  .  TFBS  7000  7009  .  +   ID=TFBS00005 
   
Figure A.5.1: Example of the GFF format. 
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A.6 The BED format 
The BED format shown in Figure A.6.1 is also a tab delimited format used for 
storing genomic information containing the following compulsory fields:  
1. chromosome 
2. start position  
3. end position 
chr7    127471196  127471211   
chr7    127472363  127472375   
chr7    127473530  127473540   
chr7    127474697  127474706   
chr7    127475864  127475877   
chr7    127477031  127477042  
chr7    127478198  127478212   
chr7    127479365  127479374   
chr7    127480532  127480542   
 
Figure A.6.1: An example of the BED format. 
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Appendix B Scripts used to generate 
hCRM PWMs 
 
Below are the various scripts that were used to generate the hCRM PWMs 
using rGADEM from the ENCODE ChIP-Seq data using the protocol 
summarised in Figure 3.2. These scripts are presented in the order that they 
need to be run.  
Script for calling peaks:  
 
#!/bin/bash 
#read alignment 
.//home/Narayan/bowtie/bowtie 
/home/Narayan/bowtie/indexes/hg19.ebwt -q 
/home/Narayan/chip-seq/ATF3.fastq_processed_1 --best -m 
1 -n 1 
#convert to bam 
.//home/Narayan/samtools/samtools view -bS 
A/home/Narayan/chip-seq/ATF3.sam >/home/Narayan/chip-
seq/ATF3_rep1.bam 
#index 
.//home/Narayan/samtools/samtools index ATF3_rep1.bam 
#convert to bed 
.//home/Narayan/BEDTools/bin/bamToBed -i 
/home/Narayan/chip-seq/ATF3_rep1.bam 
>/home/Narayan/chip-seq/ATF3_rep1.bed 
#call peaks  
.//home/Narayan/MACS/bin/macs14 -t /home/Narayan/chip-
seq/ATF3_rep1.bed -c /home/Narayan/chip-
seq/ATF3_control.bed  >ATF3_rep1_peaks.txt  
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Script for obtaining common peaks if there are replicates: 
 
library(ChIPpeakAnno) 
 
#read in files 
set1<-read.table("ATF3_rep1_peaks.txt ") 
set2<-read.table("ATF3_rep2_peaks.txt ") 
#prepare for comparison 
peaks1<-
RangedData(IRanges(start=set1[,2],end=set1[,3]),space=se
t1[,1]) 
peaks2<-
RangedData(IRanges(start=set2[,2],end=set2[,3]),space=se
t2[,1]) 
#find overlapping peaks and save 
overlapping_peaks<-subsetByOverlaps(peaks1,peaks2) 
peaks<-as.data.frame(overlapping_peaks) 
write.table(peaks,file="ATF3_peaks.txt",quote= FALSE, 
row.names = FALSE,col.names = FALSE) 
 
Script for obtaining peak regions: 
 
#!/bin/bash 
 
awk '{$6=$2+$5;$7=$6+100;$8=$6-100;print $1,$8,$7}' 
ATF3_peaks.txt >ATF3_peak_summits.txt 
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Script for converting peak regions to FASTA format: 
 
library(ChIPpeakAnno) 
library(BSgenome.Hsapiens.UCSC.hg19) 
#read in file 
data<-read.table("/home/narayan/chip-
seq/ATF3_peak_summits.txt") 
#convert to fasta and save 
peaks<RangedData(IRanges(start=data[,2],end=data[,3],nam
es=c(1:29289)),space=data[,1]) 
PeaksWithSequences<- getAllPeakSequence(peaks, upstream 
= 0,downstream = 0,genome = Hsapiens) 
write2FASTA(PeaksWithSequences,file="/home/narayan/chip-
seq/ATF3.fa") 
 
 
Script for deriving PWMs with rGADEM: 
library(rGADEM)  
#read in file 
Sequences <- read.DNAStringSet(“/home/narayan/chip-
seq/ATF3.fa”, "fasta")  
#motif discovery 
gadem<-
GADEM(Sequences,verbose=1,genome=Hsapiens,eValue=0.5,nmo
tifs=1)  
#save 
cat(gadem,file= “/home/narayan/chip-seq/ATF3_pwm.txt”) 
